

# Marc Humbert

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7517491/publications.pdf>

Version: 2024-02-01

848  
papers

91,263  
citations

397

133  
h-index

442

274  
g-index

933  
all docs

933  
docs citations

933  
times ranked

47518  
citing authors

#	ARTICLE	IF	CITATIONS
1	Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). <i>European Respiratory Journal</i> , 2022, 59, 2100396.	3.1	46
2	Different cardiovascular and pulmonary phenotypes for single- and double-knock-out mice deficient in BMP9 and BMP10. <i>Cardiovascular Research</i> , 2022, 118, 1805-1820.	1.8	26
3	Phenotypic Diversity of Vascular Smooth Muscle Cells in Pulmonary Arterial Hypertension. <i>Chest</i> , 2022, 161, 219-231.	0.4	26
4	Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2022, 59, 2002463.	3.1	31
5	Pulmonary Endarterectomy in Patients With Myeloproliferative Neoplasms. <i>Chest</i> , 2022, 161, 552-556.	0.4	4
6	Chronic thromboembolic pulmonary hypertension: the magic of pathophysiology. <i>Annals of Cardiothoracic Surgery</i> , 2022, 11, 106-119.	0.6	17
7	Health outcomes after stopping long-term mepolizumab in severe eosinophilic asthma: COMET. <i>ERJ Open Research</i> , 2022, 8, 00419-2021.	1.1	3
8	External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry. <i>European Respiratory Journal</i> , 2022, 59, 2102419.	3.1	83
9	Double-lung transplantation followed by delayed percutaneous repair for atrial septal defect-associated pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2022, 59, 2102388.	3.1	3
10	Interplay of sex hormones and long-term right ventricular adaptation in a Dutch PAH-cohort. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 445-457.	0.3	12
11	Response to: Life-threatening PPHN refractory to NO: therapeutic algorithm. <i>European Journal of Pediatrics</i> , 2022, 181, 425-426.	1.3	1
12	Pulsatile pulmonary artery pressure in a large animal model of chronic thromboembolic pulmonary hypertension: Similarities and differences with human data. <i>Pulmonary Circulation</i> , 2022, 12, e12017.	0.8	1
13	European Respiratory Society clinical practice guidelines: methodological guidance. <i>ERJ Open Research</i> , 2022, 8, 00655-2021.	1.1	6
14	Using the Plasma Proteome for Risk Stratifying Patients with Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1102-1111.	2.5	35
15	Progression of Pulmonary Venous Occlusive Disease Without Pulmonary Hypertension. <i>Pulmonary Circulation</i> , 2022, 12, e12046.	0.8	3
16	WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension. <i>European Respiratory Review</i> , 2022, 31, 210165.	3.0	28
17	Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 716-721.	0.3	28
18	Respiratory symptoms and radiological findings in post-acute COVID-19 syndrome. <i>ERJ Open Research</i> , 2022, 8, 00479-2021.	1.1	16

#	ARTICLE	IF	CITATIONS
19	Sequential combination therapy with parenteral prostacyclin in BMPR2 mutations carriers. Pulmonary Circulation, 2022, 12, e12023.	0.8	2
20	SUR1 as a New Therapeutic Target for Pulmonary Arterial Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2022, , .	1.4	10
21	ERS statement on chronic thromboembolic pulmonary hypertension. Pulmonologiya, 2022, 32, 13-52.	0.2	0
22	Finding Pulmonary Arterial Hypertensionâ€”Switching to Offense to Mitigate Disease Burden. JAMA Cardiology, 2022, 7, 369.	3.0	6
23	Post-acute COVID-19 syndrome. European Respiratory Review, 2022, 31, 210185.	3.0	105
24	Diagnostic, prognostic and differential-diagnostic relevance of pulmonary haemodynamic parameters during exercise: a systematic review. European Respiratory Journal, 2022, 60, 2103181.	3.1	27
25	Commemorating World Tuberculosis Day 2022: recent <i>ERJ</i> articles of critical relevance to ending TB and saving lives. European Respiratory Journal, 2022, 59, 2200149.	3.1	0
26	Lung Ventilation/Perfusion Scintigraphy for the Screening of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Which Criteria to Use?. Frontiers in Medicine, 2022, 9, 851935.	1.2	4
27	Pulmonary thromboendarterectomy: The Marie Lannelongue Hospital experience. Annals of Cardiothoracic Surgery, 2022, 11, 143-150.	0.6	6
28	Plateletâ€”Derived Growth Factor Receptor Type 1 Activation Drives Pulmonary Vascular Remodeling Via Progenitor Cell Proliferation and Induces Pulmonary Hypertension. Journal of the American Heart Association, 2022, 11, e023021.	1.6	5
29	Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 751-760.	2.5	27
30	Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1449-1460.	2.5	19
31	HFp2EF: heart failure with pulmonary dysfunction and preserved ejection fraction?. European Heart Journal, 2022, 43, 2209-2211.	1.0	2
32	COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 573-583.	2.5	16
33	Loss of cAbl Tyrosine Kinase in Pulmonary Arterial Hypertension Causes Dysfunction of Vascular Endothelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2022, , .	1.4	2
34	The Long March to a Cure for Pulmonary Hypertension. JACC Asia, 2022, 2, 215-217.	0.5	0
35	Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patients. European Respiratory Journal, 2022, 60, 2103130.	3.1	15
36	An emerging phenotype of pulmonary arterial hypertension patients carrying<i>SOX17</i> variants. European Respiratory Journal, 2022, 60, 2200656.	3.1	15

#	ARTICLE	IF	CITATIONS
37	Lung transplantation in HIV-positive patients: a European retrospective cohort study. <i>European Respiratory Journal</i> , 2022, 60, 2200189.	3.1	7
38	Risk stratification in patients with pulmonary arterial hypertension at the time of listing for lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 1285-1293.	0.3	6
39	To be or not to be treated with initial combination therapy, that is the (PAH) question. <i>European Respiratory Journal</i> , 2022, 59, 2200390.	3.1	2
40	Outcomes of cirrhotic patients with pre-capillary pulmonary hypertension and pulmonary vascular resistance between 2 and 3 Wood Units. <i>European Respiratory Journal</i> , 2022, 60, 2200107.	3.1	5
41	Knowledge exchange between patient and pharmacist: a mixed methods study to explore the role of pharmacists in patient education and counselling in asthma and pulmonary arterial hypertension. <i>Annales Pharmaceutiques Francaises</i> , 2022, , .	0.4	0
42	Screening for pulmonary veno-occlusive disease in heterozygous <i>EIF2AK4</i> variant carriers. <i>European Respiratory Journal</i> , 2022, 60, 2200760.	3.1	2
43	Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. <i>European Respiratory Journal</i> , 2022, 60, 2200803.	3.1	22
44	Pulmonary veno-occlusive disease associated with long-term occupational exposure to chemical solvents and pesticides. A case report. <i>Respiratory Medicine and Research</i> , 2022, , 100943.	0.4	0
45	Identifying new drugs associated with pulmonary arterial hypertension: A WHO pharmacovigilance database disproportionality analysis. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 5227-5237.	1.1	7
46	Recent advances in the management of pulmonary hypertension with interstitial lung disease. <i>European Respiratory Review</i> , 2022, 31, 210220.	3.0	13
47	Bayesian Inference Associates Rare <i>KDR</i> Variants With Specific Phenotypes in Pulmonary Arterial Hypertension. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, .	1.6	29
48	Reducing the hidden burden of severe asthma: recognition and referrals from primary practice. <i>Journal of Asthma</i> , 2021, 58, 849-854.	0.9	8
49	Preoperative C-reactive protein predicts early postoperative outcomes after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 161, 1532-1542.e5.	0.4	7
50	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 168-190.	2.7	46
51	A Fluid Challenge Test for the Diagnosis of Occult Heart Failure. <i>Chest</i> , 2021, 159, 791-797.	0.4	19
52	Sleep-related breathing disorders and pulmonary hypertension. <i>European Respiratory Journal</i> , 2021, 57, 2002258.	3.1	56
53	Lung transplantation in neonates and infants: ESPNIC survey of European neonatologists and pediatric intensivists. <i>European Journal of Pediatrics</i> , 2021, 180, 295-298.	1.3	5
54	Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension. <i>Cardiovascular Research</i> , 2021, 117, 1391-1401.	1.8	23

#	ARTICLE	IF	CITATIONS
55	Chronic thromboembolic pulmonary hypertension and totally implantable central venous access systems. <i>European Respiratory Journal</i> , 2021, 57, 2002208.	3.1	12
56	Single-Cell Study of Two Rat Models of Pulmonary Arterial Hypertension Reveals Connections to Human Pathobiology and Drug Repositioning. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1006-1022.	2.5	36
57	Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia. <i>JAMA Internal Medicine</i> , 2021, 181, 32.	2.6	654
58	Characteristics and Long-term Outcomes of Pulmonary Venoocclusive Disease Induced by Mitomycin C. <i>Chest</i> , 2021, 159, 1197-1207.	0.4	14
59	How to Assess Effectiveness of Biologics for Asthma and What Steps to Take When There Is Not Benefit. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1081-1088.	2.0	28
60	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , 2021, 178, 106220.	1.3	23
61	Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La PiÃ©ce de RÃ©sistance?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 524-525.	2.5	1
62	Reversible pulmonary hypertension associated with multivisceral Whipple's disease. <i>European Respiratory Journal</i> , 2021, 57, 2003132.	3.1	3
63	The Thousand Faces of Leptin in the Lung. <i>Chest</i> , 2021, 159, 239-248.	0.4	18
64	Targeting transforming growth factor- $\beta$ receptors in pulmonary hypertension. <i>European Respiratory Journal</i> , 2021, 57, 2002341.	3.1	67
65	Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2021, 73, 295-304.	2.9	26
66	Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2702-2714.	2.0	62
67	The evolution of the <i>European Respiratory Journal</i>: weathering the publishing pandemic. <i>European Respiratory Journal</i> , 2021, 57, 2100084.	3.1	3
68	Imaging of pulmonary hypertension in adults: a position paper from the Fleischner Society. <i>European Respiratory Journal</i> , 2021, 57, 2004455.	3.1	42
69	Acute Right-Heart Failure in Patients with Chronic Precapillary Pulmonary Hypertension. , 2021, , 301-316.		0
70	The multifaceted problem of pulmonary arterial hypertension in systemic sclerosis. <i>Lancet Rheumatology</i> , The, 2021, 3, e149-e159.	2.2	11
71	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , 2021, 177, 106241.	1.3	13
72	Kcnk3 dysfunction exaggerates the development of pulmonary hypertension induced by left ventricular pressure overload. <i>Cardiovascular Research</i> , 2021, 117, 2474-2488.	1.8	20

#	ARTICLE	IF	CITATIONS
73	Risk Stratification in Pulmonary Arterial Hypertension: Do Not Forget the Patient Perspective. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 675-677.	2.5	4
74	Imaging of Pulmonary Hypertension in Adults: A Position Paper from the Fleischner Society. Radiology, 2021, 298, 531-549.	3.6	43
75	The isobaric pulmonary arterial compliance in pulmonary hypertension. ERJ Open Research, 2021, 7, 00941-2020.	1.1	5
76	Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. European Respiratory Journal, 2021, 57, 2100048.	3.1	152
77	An endothelial activin A-bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertension. Nature Communications, 2021, 12, 1720.	5.8	30
78	Hypoxemia during sleep and overnight rostral fluid shift in pulmonary arterial hypertension: a pilot study. Pulmonary Circulation, 2021, 11, 1-9.	0.8	5
79	Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission. European Respiratory Journal, 2021, 58, 2100116.	3.1	41
80	Integrating haemodynamics identifies an extreme pulmonary hypertension phenotype. European Respiratory Journal, 2021, 58, 2004625.	3.1	12
81	Sotatercept for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2021, 384, 1204-1215.	13.9	224
82	Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs. European Respiratory Journal, 2021, 58, 2004066.	3.1	14
83	Pulmonary arterial hypertension in systemic sclerosis. Presse Medicale, 2021, 50, 104062.	0.8	6
84	Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension. European Respiratory Journal, 2021, 58, 2000653.	3.1	16
85	Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission and role for pre-test probability scores and home treatment. European Respiratory Journal, 2021, 58, 2101033.	3.1	8
86	Multidisciplinary approach for post-acute COVID-19 syndrome: time to break down the walls. European Respiratory Journal, 2021, 58, 2101090.	3.1	18
87	PH CARE COVID survey: an international patient survey on the care for pulmonary hypertension patients during the early phase of the COVID-19 pandemic. Orphanet Journal of Rare Diseases, 2021, 16, 196.	1.2	11
88	Regulation of the Methylation and Expression Levels of the BMPR2 Gene by SIN3a as a Novel Therapeutic Mechanism in Pulmonary Arterial Hypertension. Circulation, 2021, 144, 52-73.	1.6	38
89	Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 842-854.	2.5	94
90	Five-year survival after an acute episode of decompensated pulmonary arterial hypertension in the modern management era of right heart failure. European Respiratory Journal, 2021, 58, 2100466.	3.1	7

#	ARTICLE	IF	CITATIONS
91	Pulmonary hypertension associated with neurofibromatosis type 2. <i>Pulmonary Circulation</i> , 2021, 11, 1-4.	0.8	0
92	Right Ventricle Remodeling Metabolic Signature in Experimental Pulmonary Hypertension Models of Chronic Hypoxia and Monocrotaline Exposure. <i>Cells</i> , 2021, 10, 1559.	1.8	10
93	Life-threatening PPHN refractory to nitric oxide: proposal for a rational therapeutic algorithm. <i>European Journal of Pediatrics</i> , 2021, 180, 2379-2387.	1.3	17
94	Right ventricle dysfunction in patients with acute pulmonary embolism supposedly at low risk for death: when evidence-based medicine rescues clinical practice. <i>European Heart Journal</i> , 2021, 42, 3200-3202.	1.0	8
95	Pulmonary Hypertension in Patients with Common Variable Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2021, 41, 1549-1562.	2.0	3
96	Lung and heart-lung transplantation for children with PAH: Dramatic benefits from the implementation of a high-priority allocation program in France. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 652-661.	0.3	1
97	Cardiovascular phenotypes predict clinical outcomes in sickle cell disease: An echocardiography-based cluster analysis. <i>American Journal of Hematology</i> , 2021, 96, 1166-1175.	2.0	5
98	Comment on: Transcriptomic analysis of CFTR-impaired endothelial cells reveals a pro-inflammatory phenotype. <i>European Respiratory Journal</i> , 2021, 58, 2101365.	3.1	0
99	COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: Nationwide real-world evidence. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 361-367.e13.	1.5	62
100	A <i>CELSR1</i> variant in a patient with pulmonary arterial hypertension. <i>Clinical Genetics</i> , 2021, 100, 771-772.	1.0	1
101	Transplantation for pulmonary arterial hypertension with congenital heart disease: Impact on outcomes of the current therapeutic approach including a high-priority allocation program. <i>American Journal of Transplantation</i> , 2021, 21, 3388-3400.	2.6	3
102	Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9105.	1.8	10
103	Association between sex and SARS-CoV-2 infection and hospitalisation as a result of COVID-19. <i>Lancet Respiratory Medicine</i> , 2021, 9, e75-e76.	5.2	1
104	Association between Leflunomide and Pulmonary Hypertension. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1306-1315.	1.5	8
105	Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A prospective French multicenter cohort. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1009-1018.	0.3	24
106	Omalizumab Effectiveness in Severe Allergic Asthma with Multiple Allergic Comorbidities: A Post-Hoc Analysis of the STELLAIR Study. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 1129-1138.	1.5	5
107	Investigating the association between ALK Receptor Tyrosine Kinase inhibitors and pulmonary arterial hypertension: a disproportionality analysis from the WHO pharmacovigilance database. <i>European Respiratory Journal</i> , 2021, 58, 2101576.	3.1	5
108	Pulmonary hypertension associated with busulfan. <i>Pulmonary Circulation</i> , 2021, 11, 1-12.	0.8	3



#	ARTICLE	IF	CITATIONS
109	An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 1251-1258.	2.5	121
110	Looking forward: key initiatives to improve the care of rare diseases and streamline the delivery of medicines and vaccines in Europe. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 321, L616-L618.	1.3	2
111	Pulmonary hypertension. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 127, 512-513.	0.5	0
112	Serum and pulmonary uric acid in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2021, 58, 2000332.	3.1	28
113	Lung transplantation for sarcoidosis: outcome and prognostic factors. <i>European Respiratory Journal</i> , 2021, 58, 2003358.	3.1	32
114	ERS statement on chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2021, 57, 2002828.	3.1	287
115	Screening for pulmonary arterial hypertension in adults carrying a <i>BMPR2</i> mutation. <i>European Respiratory Journal</i> , 2021, 58, 2004229.	3.1	50
116	Reply to: Jin et al. and Sun et al.. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, , .	2.5	0
117	Multimodality Imaging of Pulmonary Hypertension: Prognostication of Therapeutic Outcomes. <i>Medical Radiology</i> , 2021, , 225-257.	0.0	1
118	Sex and gender in pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2021, 30, 200330.	3.0	31
119	Sex and gender in lung health and disease: more than just Xs and Ys. <i>European Respiratory Review</i> , 2021, 30, 210217.	3.0	1
120	Preventing the Increase in Lysophosphatidic Acids: A New Therapeutic Target in Pulmonary Hypertension?. <i>Metabolites</i> , 2021, 11, 784.	1.3	2
121	Success and continuous growth of the ERS clinical research collaborations. <i>European Respiratory Journal</i> , 2021, 58, 2102527.	3.1	7
122	Role of Store-Operated Ca <sup>2+</sup> Entry in the Pulmonary Vascular Remodeling Occurring in Pulmonary Arterial Hypertension. <i>Biomolecules</i> , 2021, 11, 1781.	1.8	11
123	Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. <i>Nature Communications</i> , 2021, 12, 7104.	5.8	21
124	Perioperative approach to precapillary pulmonary hypertension in non-cardiac non-obstetric surgery. <i>European Respiratory Review</i> , 2021, 30, 210166.	3.0	6
125	Smouldering fire or conflagration? An illustrated update on the concept of inflammation in pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2021, 30, 210161.	3.0	5
126	Asthma and COVID-19: an update. <i>European Respiratory Review</i> , 2021, 30, 210152.	3.0	56



#	ARTICLE	IF	CITATIONS
127	Some take-home messages from the 9th International Meeting on Pulmonary Rare Diseases and Orphan Drugs. <i>European Respiratory Review</i> , 2021, 30, 210258.	3.0	0
128	Neutralization of CXCL12 attenuates established pulmonary hypertension in rats. <i>Cardiovascular Research</i> , 2020, 116, 686-697.	1.8	54
129	A novel secreted-cAMP pathway inhibits pulmonary hypertension via a feed-forward mechanism. <i>Cardiovascular Research</i> , 2020, 116, 1500-1513.	1.8	15
130	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Heart Journal</i> , 2020, 41, 543-603.	1.0	2,426
131	Characterization of <i>GDF2</i> Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 575-585.	2.5	80
132	Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 942-946.	2.7	11
133	Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma. <i>Advances in Therapy</i> , 2020, 37, 718-729.	1.3	48
134	Intensity and quality of exertional dyspnoea in patients with stable pulmonary hypertension. <i>European Respiratory Journal</i> , 2020, 55, 1802108.	3.1	24
135	Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 124, 190-196.	0.5	39
136	Survival Improved in Patients Aged ≥ 70 Years With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension During the Period 2006 to 2017 in France. <i>Chest</i> , 2020, 157, 945-954.	0.4	13
137	Chronic inflammation within the vascular wall in pulmonary arterial hypertension: more than a spectator. <i>Cardiovascular Research</i> , 2020, 116, 885-893.	1.8	70
138	Evaluation and management of pulmonary arterial hypertension. <i>Respiratory Medicine</i> , 2020, 171, 106099.	1.3	43
139	Pandemic treatments on trial: the bigger picture. N of many thinking in an N of one scenario. <i>European Respiratory Journal</i> , 2020, 56, 2002281.	3.1	2
140	Guidance production before evidence generation for critical issues: the example of COVID-19. <i>European Respiratory Review</i> , 2020, 29, 200310.	3.0	5
141	Proteomic Analysis of KCNK3 Loss of Expression Identified Dysregulated Pathways in Pulmonary Vascular Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7400.	1.8	14
142	Large Granular Lymphocyte Leukemia and Precapillary Pulmonary Hypertension. <i>Chest</i> , 2020, 158, 2602-2609.	0.4	5
143	In vivo miR-138-5p inhibition alleviates monocrotaline-induced pulmonary hypertension and normalizes pulmonary KCNK3 and SLC45A3 expression. <i>Respiratory Research</i> , 2020, 21, 186.	1.4	20
144	Risks and outcomes of gastrointestinal endoscopy with anaesthesia in patients with pulmonary hypertension. <i>British Journal of Anaesthesia</i> , 2020, 125, e466-e468.	1.5	5

#	ARTICLE	IF	CITATIONS
145	Description, Staging and Quantification of Pulmonary Artery Angiophagy in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension. <i>Biomedicines</i> , 2020, 8, 493.	1.4	2
146	COVID-19 in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a reference centre survey. <i>ERJ Open Research</i> , 2020, 6, 00520-2020.	1.1	40
147	An update on sarcoidosis-associated pulmonary hypertension. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 582-590.	1.2	17
148	Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. <i>Lancet Respiratory Medicine</i> , 2020, 8, 873-884.	5.2	139
149	Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. <i>European Respiratory Journal</i> , 2020, 56, 2001875.	3.1	90
150	Multimodal Imaging Mass Spectrometry to Identify Markers of Pulmonary Arterial Hypertension in Human Lung Tissue Using MALDI-ToF, ToF-SIMS, and Hybrid SIMS. <i>Analytical Chemistry</i> , 2020, 92, 12079-12087.	3.2	33
151	Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies). <i>Pulmonary Circulation</i> , 2020, 10, 1-10.	0.8	4
152	Gas Exchange and Ventilatory Efficiency During Exercise in Pulmonary Vascular Diseases. <i>Archivos De Bronconeumologia</i> , 2020, 56, 578-585.	0.4	5
153	Implication of Potassium Channels in the Pathophysiology of Pulmonary Arterial Hypertension. <i>Biomolecules</i> , 2020, 10, 1261.	1.8	27
154	Ultra-rare disease: an European perspective. <i>European Respiratory Review</i> , 2020, 29, 200195.	3.0	10
155	Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 586-594.	2.5	45
156	Pulmonary Hypertension Complicating Pulmonary Artery Involvement in Pseudoxanthoma Elasticum. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, e90-e91.	2.5	1
157	Severe Pulmonary Hypertension Management Across Europe (PHAROS): an ERS Clinical Research Collaboration. <i>European Respiratory Journal</i> , 2020, 55, 2001047.	3.1	3
158	Which patients are SaPHe in sarcoidosis-associated pulmonary hypertension?. <i>European Respiratory Journal</i> , 2020, 55, 2000700.	3.1	1
159	Pulmonary capillary haemangiomatosis: a distinct entity?. <i>European Respiratory Review</i> , 2020, 29, 190168.	3.0	17
160	Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 843-852.	2.5	12
161	Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors. <i>European Respiratory Journal</i> , 2020, 56, 2000279.	3.1	28
162	Whole-genome sequencing of patients with rare diseases in a national health system. <i>Nature</i> , 2020, 583, 96-102.	13.7	338

#	ARTICLE	IF	CITATIONS
163	Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?. <i>European Respiratory Journal</i> , 2020, 56, 2001634.	3.1	284
164	Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SVa€NHIBITION study design. <i>ESC Heart Failure</i> , 2020, 7, 747-756.	1.4	9
165	Phenotype and outcome of pulmonary arterial hypertension patients carrying a <i>TBX4</i> mutation. <i>European Respiratory Journal</i> , 2020, 55, 1902340.	3.1	40
166	Portopulmonary hypertension in the current era of pulmonary hypertension management. <i>Journal of Hepatology</i> , 2020, 73, 130-139.	1.8	78
167	Diagnosis of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. <i>European Respiratory Journal</i> , 2020, 55, 2000189.	3.1	55
168	The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. <i>Radiology</i> , 2020, 296, 172-180.	3.6	721
169	Trichloroethylene increases pulmonary endothelial permeability: implication for pulmonary veno€occlusive disease. <i>Pulmonary Circulation</i> , 2020, 10, 1-4.	0.8	4
170	Rapid onset honeycombing fibrosis in spontaneously breathing patient with COVID-19. <i>European Respiratory Journal</i> , 2020, 56, 2001808.	3.1	38
171	Adding an important piece to the pulmonary vascular resistance puzzle in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2020, 56, 2000962.	3.1	1
172	Schistosomiasis-associated pulmonary arterial hypertension: a systematic review. <i>European Respiratory Review</i> , 2020, 29, 190089.	3.0	40
173	Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. <i>Lancet Respiratory Medicine</i> .the, 2020, 8, 461-474.	5.2	56
174	<i>Staphylococcus aureus</i> and its IgE-inducing enterotoxins in asthma: current knowledge. <i>European Respiratory Journal</i> , 2020, 55, 1901592.	3.1	71
175	Lineage Tracing Reveals the Dynamic Contribution of Pericytes to the Blood Vessel Remodeling in Pulmonary Hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 766-782.	1.1	44
176	Familial pulmonary arterial hypertension by <i>KDR</i> heterozygous loss of function. <i>European Respiratory Journal</i> , 2020, 55, 1902165.	3.1	49
177	Excitation-contraction coupling and relaxation alteration in right ventricular remodelling caused by pulmonary arterial hypertension. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 70-84.	0.7	19
178	The Role of Chest Imaging in Patient Management During the COVID-19 Pandemic. <i>Chest</i> , 2020, 158, 106-116.	0.4	832
179	The €great wait€™ for diagnosis in pulmonary arterial hypertension. <i>Respirology</i> , 2020, 25, 790-792.	1.3	8
180	Comparison of Human and Experimental Pulmonary Veno-Occlusive Disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2020, 63, 118-131.	1.4	24

#	ARTICLE	IF	CITATIONS
181	Mendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2020, 55, 1901486.	3.1	26
182	Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme. <i>European Respiratory Journal</i> , 2020, 55, 1902345.	3.1	57
183	Pulmonary Veno-occlusive Disease and Pulmonary Capillary Hemangiomas. <i>Respiratory Medicine</i> , 2020, , 89-108.	0.1	1
184	Gas Exchange and Ventilatory Efficiency During Exercise in Pulmonary Vascular Diseases. <i>Archivos De Bronconeumologia</i> , 2020, 56, 578-585.	0.4	10
185	Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study. <i>PLoS ONE</i> , 2020, 15, e0243961.	1.1	15
186	Evaluation of a collaborative care program for pulmonary hypertension patients: a multicenter randomized trial. <i>International Journal of Clinical Pharmacy</i> , 2020, 42, 1128-1138.	1.0	4
187	Interstitial lung diseases in the 2020s. <i>Presse Medicale</i> , 2020, 49, 104022.	0.8	0
188	Cardiovascular implications of pulmonary hypertension due to chronic respiratory diseases. , 2020, , 167-183.		0
189	Pulmonary Hypertension in Sickle Cell Disease: Current Controversies and Clinical Practices. <i>Respiratory Medicine</i> , 2020, , 123-134.	0.1	1
190	Title is missing!. , 2020, 15, e0243961.		0
191	Title is missing!. , 2020, 15, e0243961.		0
192	Title is missing!. , 2020, 15, e0243961.		0
193	Title is missing!. , 2020, 15, e0243961.		0
194	Characterization of <i>Kcnk3</i> -Mutated Rat, a Novel Model of Pulmonary Hypertension. <i>Circulation Research</i> , 2019, 125, 678-695.	2.0	70
195	Screening for pulmonary arterial hypertension in systemic sclerosis. <i>European Respiratory Review</i> , 2019, 28, 190023.	3.0	59
196	Outpatient management of patients with low-risk pulmonary embolism: another piece of evidence. <i>European Heart Journal</i> , 2019, 41, 519-521.	1.0	2
197	Smooth Muscle Phenotype in Idiopathic Pulmonary Hypertension: Hyper-Proliferative but not Cancerous. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3575.	1.8	17
198	Efficacy of immunosuppressants with bridge vasodilator therapy in severe <i>lupus erythematosus</i> -associated pulmonary arterial hypertension. <i>ESC Heart Failure</i> , 2019, 6, 1322-1325.	1.4	9

#	ARTICLE	IF	CITATIONS
199	A roadmap for management of chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 54, 1901295.	3.1	13
200	Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study. <i>Clinical Therapeutics</i> , 2019, 41, 2041-2056.e5.	1.1	102
201	Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation. <i>Circulation</i> , 2019, 140, 1409-1425.	1.6	54
202	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Respiratory Journal</i> , 2019, 54, 1901647.	3.1	806
203	Hospital burden of pulmonary arterial hypertension in France. <i>PLoS ONE</i> , 2019, 14, e0221211.	1.1	9
204	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. <i>Clinical and Translational Allergy</i> , 2019, 9, 44.	1.4	87
205	Golden Ratio and the Proportionality Between Pulmonary Pressure Components in Pulmonary Arterial Hypertension. <i>Chest</i> , 2019, 155, 991-998.	0.4	13
206	Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility. <i>Respiratory Medicine</i> , 2019, 154, 69-75.	1.3	28
207	Pulmonary arterial hypertension in patient treated for multiple sclerosis with 4-aminopyridine. <i>Fundamental and Clinical Pharmacology</i> , 2019, 33, 426-427.	1.0	1
208	Germline selection shapes human mitochondrial DNA diversity. <i>Science</i> , 2019, 364, .	6.0	178
209	Response by Guignabert et al to Letter Regarding Article, "Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension". <i>Circulation Research</i> , 2019, 124, e82-e83.	2.0	2
210	Predictors of survival in patients with not-operated chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 833-842.	0.3	57
211	Indications and potential pitfalls of anticoagulants in pulmonary hypertension: Would DOACs become a better option than VKAs?. <i>Blood Reviews</i> , 2019, 37, 100579.	2.8	16
212	French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1802095.	3.1	173
213	Seeing the Forest for the (Arterial) Tree: Vascular Pruning and the Chronic Obstructive Pulmonary Disease Pulmonary Vascular Phenotype. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 406-408.	2.5	12
214	Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance-pharmacodynamic study. <i>European Respiratory Journal</i> , 2019, 53, 1802472.	3.1	37
215	An insider view on the World Symposium on Pulmonary Hypertension. <i>Lancet Respiratory Medicine</i> , the, 2019, 7, 484-485.	5.2	9
216	Pulmonary Arterial Histologic Lesions in Patients With COPD With Severe Pulmonary Hypertension. <i>Chest</i> , 2019, 156, 33-44.	0.4	37

#	ARTICLE	IF	CITATIONS
217	The new haemodynamic definition of pulmonary hypertension: evidence prevails, finally!. European Respiratory Journal, 2019, 53, 1900038.	3.1	44
218	Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1802004.	3.1	68
219	Understanding the Similarities and Differences between Hepatic and Pulmonary Veno-Occlusive Disease. American Journal of Pathology, 2019, 189, 1159-1175.	1.9	19
220	IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1418-1429.	2.0	64
221	The BET Bromodomain Inhibitor I-BET-151 Induces Structural and Functional Alterations of the Heart Mitochondria in Healthy Male Mice and Rats. International Journal of Molecular Sciences, 2019, 20, 1527.	1.8	17
222	Lysyl oxidase—a possible role in systemic sclerosis-associated pulmonary hypertension: a multicentre study. Rheumatology, 2019, 58, 1547-1555.	0.9	15
223	Pulmonary arterial hypertension registries: past, present and into the future. European Respiratory Review, 2019, 28, 190128.	3.0	8
224	Severe T2-high asthma in the biologics era: European experts' opinion. European Respiratory Review, 2019, 28, 190054.	3.0	32
225	Rebuttal From Drs Humbert and Lau. Chest, 2019, 156, 1045-1046.	0.4	0
226	Screening strategies for pulmonary arterial hypertension. European Heart Journal Supplements, 2019, 21, K9-K20.	0.0	44
227	POINT: Should Initial Combination Therapy Be the Standard of Care in Pulmonary Arterial Hypertension? Yes. Chest, 2019, 156, 1039-1042.	0.4	6
228	Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease. European Respiratory Journal, 2019, 54, 1900585.	3.1	15
229	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respiratory Medicine, 2019, 7, 227-238.	5.2	122
230	Functional interaction between PDGF $\beta$ and GluN2B-containing NMDA receptors in smooth muscle cell proliferation and migration in pulmonary arterial hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 316, L445-L455.	1.3	12
231	Widening the landscape of heritable pulmonary hypertension mutations in paediatric and adult cases. European Respiratory Journal, 2019, 53, 1801371.	3.1	72
232	Therapeutic effect of pirfenidone in the sugen/hypoxia rat model of severe pulmonary hypertension. FASEB Journal, 2019, 33, 3670-3679.	0.2	22
233	Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension. Circulation Research, 2019, 124, 846-855.	2.0	81
234	Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. European Respiratory Journal, 2019, 53, 1801887.	3.1	776

#	ARTICLE	IF	CITATIONS
235	<i>Bmpr2</i> Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension. <i>Circulation</i> , 2019, 139, 932-948.	1.6	74
236	Prostacyclin for pulmonary arterial hypertension. <i>The Cochrane Library</i> , 2019, 2019, CD012785.	1.5	32
237	Inhibition of B cell-dependent lymphoid follicle formation prevents lymphocytic bronchiolitis after lung transplantation. <i>JCI Insight</i> , 2019, 4, .	2.3	28
238	Late Breaking Abstract - Screening of pulmonary arterial hypertension in asymptomatic <i>BMPR2</i> mutation carriers (DELPHI-2 Study). , 2019, , .		1
239	Rare pulmonary disease and orphan drugs: a path to the future. <i>European Respiratory Review</i> , 2019, 28, 190115.	3.0	1
240	Design, Synthesis, and Biological Activity of New N-(Phenylmethyl)-benzoxazol-2-thiones as Macrophage Migration Inhibitory Factor (MIF) Antagonists: Efficacies in Experimental Pulmonary Hypertension. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2725-2736.	2.9	20
241	Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry. <i>Respiration</i> , 2018, 95, 244-250.	1.2	17
242	Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era. <i>European Respiratory Review</i> , 2018, 27, 180004.	3.0	21
243	Rapid Contour-based Segmentation for <sup>18</sup> F-FDG PET Imaging of Lung Tumors by Using ITK-SNAP: Comparison to Expert-based Segmentation. <i>Radiology</i> , 2018, 288, 277-284.	3.6	20
244	Ca <sup>2+</sup> handling remodeling and <i>STIM1</i> / <i>Orai1</i> / <i>TRPC1</i> / <i>TRPC4</i> upregulation in monocrotaline-induced right ventricular hypertrophy. <i>Journal of Molecular and Cellular Cardiology</i> , 2018, 118, 208-224.	0.9	58
245	Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. <i>Nature Communications</i> , 2018, 9, 1416.	5.8	279
246	Telomecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data. <i>Scientific Reports</i> , 2018, 8, 1300.	1.6	48
247	NMDA-Type Glutamate Receptor Activation Promotes Vascular Remodeling and Pulmonary Arterial Hypertension. <i>Circulation</i> , 2018, 137, 2371-2389.	1.6	75
248	Sirtuin 1 regulates pulmonary artery smooth muscle cell proliferation. <i>Journal of Hypertension</i> , 2018, 36, 1164-1177.	0.3	48
249	Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 166-174.	2.5	17
250	RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study. <i>Lung</i> , 2018, 196, 157-164.	1.4	42
251	Loss of <i>KCNK3</i> is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension. <i>Cardiovascular Research</i> , 2018, 114, 880-893.	1.8	52
252	Dasatinib increases endothelial permeability leading to pleural effusion. <i>European Respiratory Journal</i> , 2018, 51, 1701096.	3.1	50



#	ARTICLE	IF	CITATIONS
253	Reply to Frachon: Amphetamine Derivatives and the Risk of Pulmonary Arterial Hypertension: A Missing Chapter of the Story?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1364-1365.	2.5	0
254	Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension. Chest, 2018, 154, 136-147.	0.4	18
255	The Low-Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal-oriented Clinical Trial Endpoints?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 860-868.	2.5	45
256	Respiratory effects of trichloroethylene. Respiratory Medicine, 2018, 134, 47-53.	1.3	37
257	Natural History over 8 Years of Pulmonary Vascular Disease in a Patient Carrying Biallelic <i>EIF2AK4</i> Mutations. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 537-541.	2.5	12
258	Risk assessment in pulmonary arterial hypertension. European Respiratory Journal, 2018, 51, 1800279.	3.1	26
259	Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. European Respiratory Journal, 2018, 51, 1702523.	3.1	186
260	Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-2 studies. Pulmonary Circulation, 2018, 8, 1-4.	0.8	26
261	Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases. European Respiratory Journal, 2018, 51, 1700745.	3.1	136
262	Validation of a risk assessment instrument for pulmonary arterial hypertension. European Heart Journal, 2018, 39, 4182-4185.	1.0	16
263	Pulmonary Hypertension in Parenchymal Lung Diseases. Chest, 2018, 153, 217-223.	0.4	32
264	Amphetamine Derivatives and the Risk of Pulmonary Arterial Hypertension. A New Chapter of the Story. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 704-706.	2.5	6
265	Controversies and opportunities in severe asthma. Current Opinion in Pulmonary Medicine, 2018, 24, 83-93.	1.2	9
266	Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. Journal of Heart and Lung Transplantation, 2018, 37, 647-655.	0.3	50
267	Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. Circulation, 2018, 137, 693-704.	1.6	155
268	Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus. Chest, 2018, 153, 143-151.	0.4	68
269	After asthma: redefining airways diseases. Lancet, The, 2018, 391, 350-400.	6.3	744
270	Increasing confidence in the therapeutic relevance of eosinophils in severe asthma. Lancet Respiratory Medicine, the, 2018, 6, 7-8.	5.2	2

#	ARTICLE	IF	CITATIONS
271	Contribution of Impaired Parasympathetic Activity to Right Ventricular Dysfunction and Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2018, 137, 910-924.	1.6	83
272	Biomarker-based corticosteroid adjustment in severe asthma: a modified Delphi consensus. <i>ERJ Open Research</i> , 2018, 4, 00081-2018.	1.1	4
273	Macrophage Migration Inhibitory Factor (MIF) Inhibition in a Murine Model of Bleomycin-Induced Pulmonary Fibrosis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 4105.	1.8	21
274	Lessons from pulmonary hypertension registries. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2018, 37, 759-761.	0.2	0
275	Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease. <i>European Respiratory Journal</i> , 2018, 52, 1800272.	3.1	21
276	Loss-of-Function <i>ABCC8</i> Mutations in Pulmonary Arterial Hypertension. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002087.	1.6	62
277	Ion Channels in Pulmonary Hypertension: A Therapeutic Interest?. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3162.	1.8	61
278	Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2018, 52, 1800678.	3.1	60
279	Pulmonary hypertension associated with neurofibromatosis type 1. <i>European Respiratory Review</i> , 2018, 27, 180053.	3.0	25
280	Lessons from pulmonary hypertension registries. <i>Revista Portuguesa De Cardiologia</i> , 2018, 37, 759-761.	0.2	1
281	Poor Subpleural Perfusion Predicts Failure After Balloon Pulmonary Angioplasty for Nonoperable Chronic Thromboembolic Pulmonary Hypertension. <i>Chest</i> , 2018, 154, 521-531.	0.4	22
282	Right heart catheterisation is still a fundamental part of the follow-up assessment of pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2018, 52, 1800738.	3.1	15
283	Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis. <i>PLoS ONE</i> , 2018, 13, e0197112.	1.1	47
284	Factors predicting outcome after pulmonary endarterectomy. <i>PLoS ONE</i> , 2018, 13, e0198198.	1.1	29
285	Reply to Voelkel and Newman: The Light at the End of the Long Pulmonary Hypertension Tunnel Brightens. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 820-821.	2.5	0
286	Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension. <i>Chest</i> , 2018, 154, 872-881.	0.4	43
287	Clinical and Hemodynamic Correlates of Pulmonary Arterial Stiffness in Incident, Untreated Patients With Idiopathic Pulmonary Arterial Hypertension. <i>Chest</i> , 2018, 154, 882-892.	0.4	10
288	Impact of the initiation of balloon pulmonary angioplasty program on referral of patients with chronic thromboembolic pulmonary hypertension to surgery. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 1102-1110.	0.3	20

#	ARTICLE	IF	CITATIONS
289	Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype?. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1000-1011.	2.5	111
290	Hypertension pulmonaire et connectivites. Revue Du Rhumatisme Monographies, 2018, 85, 210-220.	0.0	0
291	Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension. International Journal of Clinical Pharmacy, 2018, 40, 790-794.	1.0	5
292	Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting Î2-agonists (ICS/LABA) in patients with uncontrolled asthma: An open-label, randomized, controlled trial. Respiratory Medicine, 2018, 141, 111-120.	1.3	11
293	Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension. Journal of Clinical Investigation, 2018, 128, 1956-1970.	3.9	125
294	Initial dual oral combination therapy in inoperable chronic thromboembolic pulmonary hypertension (CTEPH)., 2018, , .		3
295	Reappraising the effects of pulmonary artery wedge pressure on right ventricular pulsatile loading. , 2018, , .		1
296	Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. Chest, 2017, 151, 468-480.	0.4	79
297	Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study. Journal of Heart and Lung Transplantation, 2017, 36, 509-519.	0.3	22
298	The ambition of the <i>European Respiratory Journal</i> continues: chapter 5. European Respiratory Journal, 2017, 49, 1602393.	3.1	1
299	Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. Lancet Respiratory Medicine,the, 2017, 5, 125-134.	5.2	123
300	Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study. Archives of Cardiovascular Diseases, 2017, 110, 303-316.	0.7	37
301	Volatolomics of breath as an emerging frontier in pulmonary arterial hypertension. European Respiratory Journal, 2017, 49, 1601897.	3.1	32
302	Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Annals of the Rheumatic Diseases, 2017, 76, 422-426.	0.5	108
303	Gutâ€“Lung Connection in Pulmonary Arterial Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2017, 56, 402-405.	1.4	34
304	Novelties in the Treatment of Pulmonary Hypertension. Archivos De Bronconeumologia, 2017, 53, 235-236.	0.4	0
305	Severe eosinophilic asthma: a roadmap toÂconsensus. European Respiratory Journal, 2017, 49, 1700634.	3.1	143
306	Managing asthma in the era of biological therapies. Lancet Respiratory Medicine,the, 2017, 5, 376-378.	5.2	14

#	ARTICLE	IF	CITATIONS
307	Pulmonary veno-occlusive disease as an occupational lung disease. <i>Lancet Respiratory Medicine</i> , 2017, 5, e19.	5.2	4
308	Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. <i>Lancet Respiratory Medicine</i> , 2017, 5, 717-726.	5.2	99
309	Impact of High-Priority Allocation on Lung and Heart-Lung Transplantation for Pulmonary Hypertension. <i>Annals of Thoracic Surgery</i> , 2017, 104, 404-411.	0.7	29
310	Novel targets of omalizumab in asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2017, 23, 56-61.	1.2	15
311	Rare respiratory diseases are ready for primetime: from Rare Disease Day to the European Reference Networks. <i>European Respiratory Journal</i> , 2017, 49, 1700085.	3.1	30
312	Epidemiology and treatment of pulmonary arterial hypertension. <i>Nature Reviews Cardiology</i> , 2017, 14, 603-614.	6.1	310
313	Eosinophil-rich tissue infiltrates in chronic myelomonocytic leukemia patients. <i>Leukemia and Lymphoma</i> , 2017, 58, 2875-2879.	0.6	3
314	Dead-space ventilation is linked to exercise capacity and survival in distal chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 1234-1242.	0.3	37
315	Use of $\beta$ -Blockers in Pulmonary Hypertension. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	56
316	Novelties in the Treatment of Pulmonary Hypertension. <i>Archivos De Bronconeumologia</i> , 2017, 53, 235-236.	0.4	2
317	Response to the article "Sorafenib as a potential strategy for refractory pulmonary arterial hypertension". <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 45, 11-12.	1.1	3
318	Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis "A <sc>ELFOREA</sc>" <sc>ARIA</sc>" <sc>EPOS</sc>" <sc>AIRWAYS ICP</sc> statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1297-1305.	2.7	130
319	Restoring BMPRII functions in pulmonary arterial hypertension: opportunities, challenges and limitations. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 181-190.	1.5	34
320	Revisiting <sc>T</sc>ype 2 "high and <sc>T</sc>ype 2 "low airway inflammation in asthma: current knowledge and therapeutic implications. <i>Clinical and Experimental Allergy</i> , 2017, 47, 161-175.	1.4	287
321	Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 360, 267-279.	1.3	42
322	Long-term outcome in liver transplantation candidates with portopulmonary hypertension. <i>Hepatology</i> , 2017, 65, 1683-1692.	3.6	68
323	Diagnosis and Classification of 17 Diseases from 1404 Subjects <i>via</i> Pattern Analysis of Exhaled Molecules. <i>ACS Nano</i> , 2017, 11, 112-125.	7.3	386
324	Phenotypic Characterization of <i>EIF2AK4</i> Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. <i>Circulation</i> , 2017, 136, 2022-2033.	1.6	111

#	ARTICLE	IF	CITATIONS
325	Pulmonary hypertension in systemic sclerosis: different phenotypes. <i>European Respiratory Review</i> , 2017, 26, 170056.	3.0	97
326	Medical Treatment of Pulmonary Arterial Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 686-700.	0.8	9
327	Evolving Concepts in Pulmonary Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 559-560.	0.8	0
328	Prostacyclin for pulmonary hypertension. <i>The Cochrane Library</i> , 2017, , .	1.5	0
329	Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. <i>European Respiratory Journal</i> , 2017, 50, 1700465.	3.1	111
330	A unique event for the francophone respiratory community. <i>European Respiratory Journal</i> , 2017, 50, 1701479.	3.1	0
331	Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?. <i>Current Hypertension Reports</i> , 2017, 19, 86.	1.5	19
332	Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials. <i>Rheumatology</i> , 2017, 56, v33-v37.	0.9	4
333	Rare pulmonary diseases: a common fight. <i>European Respiratory Review</i> , 2017, 26, 170059.	3.0	3
334	Heritable pulmonary hypertension: from bench to bedside. <i>European Respiratory Review</i> , 2017, 26, 170037.	3.0	24
335	Challenging the concept of adding more drugs in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2017, 50, 1701527.	3.1	7
336	Are indexed values better for defining exercise pulmonary hypertension?. <i>European Respiratory Journal</i> , 2017, 50, 1700240.	3.1	4
337	Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. <i>European Respiratory Journal</i> , 2017, 50, 1700217.	3.1	89
338	Novel Treatments for Airway Disease. <i>New England Journal of Medicine</i> , 2017, 377, 595-598.	13.9	1
339	Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 2209-2221.	2.9	17
340	Immune checkpoint inhibitor-associated interstitial lung diseases: some progress but still many issues. <i>European Respiratory Journal</i> , 2017, 50, 1701319.	3.1	8
341	Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2017, 50, 1700889.	3.1	527
342	Care pathways for the selection of a biologic in severe asthma. <i>European Respiratory Journal</i> , 2017, 50, 1701782.	3.1	79

#	ARTICLE	IF	CITATIONS
343	Acute decompensated pulmonary hypertension. <i>European Respiratory Review</i> , 2017, 26, 170092.	3.0	48
344	Lung transplantation for mitomycin-induced pulmonary veno-occlusive disease. <i>Presse Medicale</i> , 2017, 46, 1223-1225.	0.8	5
345	TASK-1 (KCNK3) channels in the lung: from cell biology to clinical implications. <i>European Respiratory Journal</i> , 2017, 50, 1700754.	3.1	60
346	No genetic association detected with mepolizumab efficacy in severe asthma. <i>Respiratory Medicine</i> , 2017, 132, 178-180.	1.3	23
347	T-type Ca <sup>2+</sup> channels elicit pro-proliferative and anti-apoptotic responses through impaired PP2A/Akt1 signaling in PSMCs from patients with pulmonary arterial hypertension. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2017, 1864, 1631-1641.	1.9	21
348	Genetics of pulmonary hypertension in the clinic. <i>Current Opinion in Pulmonary Medicine</i> , 2017, 23, 386-391.	1.2	16
349	A Clinical and Echocardiographic Score to Identify Pulmonary Hypertension Due to HFpEF. <i>Journal of Cardiac Failure</i> , 2017, 23, 29-35.	0.7	25
350	Long-term outcomes of pulmonary arterial hypertension under specific drug therapy in Eisenmenger syndrome. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 386-398.	0.3	15
351	Bromodomain and extra-terminal protein mimic <sc>JQ1</sc> decreases inflammation in human vascular endothelial cells: Implications for pulmonary arterial hypertension. <i>Respirology</i> , 2017, 22, 157-164.	1.3	45
352	Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Autoimmunity Reviews</i> , 2017, 16, 1-9.	2.5	140
353	Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA. <i>Journal of Nutrition, Health and Aging</i> , 2017, 21, 92-104.	1.5	47
354	Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 583-595.	2.5	113
355	An official European Respiratory Society statement: pulmonary haemodynamics during exercise. <i>European Respiratory Journal</i> , 2017, 50, 1700578.	3.1	222
356	Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled. <i>European Respiratory Review</i> , 2017, 26, 170093.	3.0	64
357	A genome-wide association analysis identifies PDE1A DNAJC10 locus on chromosome 2 associated with idiopathic pulmonary arterial hypertension in a Japanese population. <i>Oncotarget</i> , 2017, 8, 74917-74926.	0.8	15
358	Pulmonary endothelial cell DNA methylation signature in pulmonary arterial hypertension. <i>Oncotarget</i> , 2017, 8, 52995-53016.	0.8	42
359	Clinical Assessment of Pulmonary Hypertension. , 2017, , 403-409.		0
360	Architecture gÃ©nÃ©tique de lâ€™hypertension pulmonaire : des gÃ©nes aux mÃ©dicaments. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2017, 201, 879-893.	0.0	0

#	ARTICLE	IF	CITATIONS
361	Direct-Acting Antiviral Medications for Hepatitis C Virus Infection and Pulmonary Arterial Hypertension. <i>Chest</i> , 2016, 150, 256-258.	0.4	12
362	Response to Letter Regarding Article, "Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Model". <i>Circulation</i> , 2016, 133, e592-3.	1.6	4
363	Toward better management of rare and orphan pulmonary diseases. <i>European Respiratory Journal</i> , 2016, 47, 1334-1335.	3.1	5
364	Pulmonary arterial hypertension in idiopathic inflammatory myopathies. <i>Medicine (United States)</i> , 2016, 95, e4911.	0.4	40
365	Targeting immunoglobulin E in non-atopic asthma: crossing the red line?. <i>European Respiratory Journal</i> , 2016, 48, 1538-1540.	3.1	4
366	<i>BMPR2</i> mutation status influences bronchial vascular changes in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2016, 48, 1668-1681.	3.1	68
367	To stress or not to stress? Exercise pulmonary haemodynamic testing in systemic sclerosis. <i>European Respiratory Journal</i> , 2016, 48, 1549-1552.	3.1	3
368	Risk assessment in pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2016, 25, 390-398.	3.0	39
369	Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity. <i>European Respiratory Journal</i> , 2016, 48, 1517-1519.	3.1	44
370	Interferon-induced pulmonary hypertension. <i>Current Opinion in Pulmonary Medicine</i> , 2016, 22, 415-420.	1.2	28
371	Pulmonary hypertension. <i>Current Opinion in Pulmonary Medicine</i> , 2016, 22, 399.	1.2	1
372	ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. <i>Clinical and Translational Allergy</i> , 2016, 6, 47.	1.4	121
373	Pulmonary veno-occlusive disease. <i>European Respiratory Journal</i> , 2016, 47, 1518-1534.	3.1	289
374	Initial dual oral combination therapy in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2016, 47, 1727-1736.	3.1	124
375	Lung capillary blood volume and membrane diffusion in precapillary pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 647-656.	0.3	10
376	Blood Eosinophils and Serum IgE Predict Response to Omalizumab in Patients with Severe Allergic Asthma: Innovate Trial Post-Hoc Analysis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, AB16.	1.5	6
377	Homoarginine predicts mortality in treatment-naïve patients with pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2016, 217, 12-15.	0.8	10
378	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 367-374.e2.	1.5	128



#	ARTICLE	IF	CITATIONS
379	Diagnostic concordance of different criteria for exercise pulmonary hypertension in subjects with normal resting pulmonary artery pressure. <i>European Respiratory Journal</i> , 2016, 48, 254-257.	3.1	31
380	Pulmonary complications of type 1 neurofibromatosis. <i>Revue Des Maladies Respiratoires</i> , 2016, 33, 460-473.	1.7	14
381	AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation. <i>European Respiratory Journal</i> , 2016, 47, 1028-1033.	3.1	50
382	BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. <i>Lancet Respiratory Medicine</i> , 2016, 4, 129-137.	5.2	307
383	Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. <i>Lancet Respiratory Medicine</i> , 2016, 4, 361-371.	5.2	97
384	Role for Runt-related Transcription Factor 2 in Proliferative and Calcified Vascular Lesions in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1273-1285.	2.5	88
385	Bone Morphogenetic Protein Receptor Type 2 Mutation in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2016, 133, 1747-1760.	1.6	75
386	Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>European Respiratory Journal</i> , 2016, 48, 1429-1441.	3.1	102
387	Should we use gait speed in COPD, FEV <sub>1</sub> in frailty and dyspnoea in both?. <i>European Respiratory Journal</i> , 2016, 48, 315-319.	3.1	19
388	Proteomic analysis of vascular smooth muscle cells in physiological condition and in pulmonary arterial hypertension: Toward contractile versus synthetic phenotypes. <i>Proteomics</i> , 2016, 16, 2637-2649.	1.3	25
389	Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). <i>Clinical and Translational Allergy</i> , 2016, 6, 29.	1.4	47
390	Clinical trials: registration and transparency. <i>European Respiratory Journal</i> , 2016, 47, 1342-1344.	3.1	6
391	Resting pulmonary artery pressure of 21-24 mmHg predicts abnormal exercise haemodynamics. <i>European Respiratory Journal</i> , 2016, 47, 1436-1444.	3.1	44
392	Resident PW1 Progenitor Cells Participate in Vascular Remodeling During Pulmonary Arterial Hypertension. <i>Circulation Research</i> , 2016, 118, 822-833.	2.0	34
393	Loss of Vascular Distensibility During Exercise Is an Early Hemodynamic Marker of Pulmonary Vascular Disease. <i>Chest</i> , 2016, 149, 353-361.	0.4	55
394	2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 177.	0.4	210
395	Treatable traits: toward precision medicine of chronic airway diseases. <i>European Respiratory Journal</i> , 2016, 47, 410-419.	3.1	746
396	Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension. <i>Chest</i> , 2016, 149, 1482-1493.	0.4	63

#	ARTICLE	IF	CITATIONS
397	Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH). <i>Current Rheumatology Reports</i> , 2016, 18, 10.	2.1	38
398	A global view of pulmonary hypertension. <i>Lancet Respiratory Medicine</i> , 2016, 4, 306-322.	5.2	523
399	CardioPulse ArticlesWhat's new in the European Society of Cardiology/European Respiratory Society Pulmonary Hypertension Guidelines?The Ten Commandments for 2015 European Society of Cardiologyâ€“European Respiratory Society Guidelines on Pulmonary HypertensionNewEHJinternational editorial board membersEHJSupplementâ€“the Heart of the Matter, UPDATE: Table 1. <i>European Heart Journal</i> , 2016, 37, 4-11.	1.0	23
400	Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension. <i>Circulation</i> , 2016, 133, 1371-1385.	1.6	141
401	A rare case of sarcoidosis-associated pulmonary hypertension in a patient exposed to silica. <i>European Respiratory Review</i> , 2016, 25, 93-96.	3.0	7
402	Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension. <i>Drug Safety</i> , 2016, 39, 287-294.	1.4	35
403	The ambition of the <i>European Respiratory Journal</i>: chapter 4. <i>European Respiratory Journal</i> , 2016, 47, 1-4.	3.1	4
404	Genetic counselling in a national referral centre for pulmonary hypertension. <i>European Respiratory Journal</i> , 2016, 47, 541-552.	3.1	87
405	The molecular targets of approved treatments for pulmonary arterial hypertension. <i>Thorax</i> , 2016, 71, 73-83.	2.7	126
406	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. <i>European Heart Journal</i> , 2016, 37, 67-119.	1.0	5,074
407	A prospective study of the 6â€“min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1457-1465.	0.5	16
408	Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. <i>Journal of Clinical Investigation</i> , 2016, 126, 3207-3218.	3.9	208
409	2015 ESC/ERS GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION. <i>Russian Journal of Cardiology</i> , 2016, , 5-64.	0.4	15
410	The Ten Commandments for 2015 European Society of Cardiologyâ€“European Respiratory Society Guidelines on Pulmonary Hypertension. <i>European Heart Journal</i> , 2016, 37, 5.	1.0	3
411	Pulmonary arterial hypertension in patients treated with interferon. <i>European Respiratory Journal</i> , 2015, 46, 1851-1853.	3.1	35
412	Does Circulating IL-17 Identify a Subset of Patients With Idiopathic Pulmonary Arterial Hypertension?: Response. <i>Chest</i> , 2015, 148, e132-e133.	0.4	0
413	MACVIA-ARIA Sentinel Network for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 1372-1392.	2.7	160
414	Characteristics of Pulmonary Arterial Hypertension in Affected Carriers of a Mutation Located in the Cytoplasmic Tail of Bone Morphogenetic Protein Receptor Type 2. <i>Chest</i> , 2015, 147, 1385-1394.	0.4	33

#	ARTICLE	IF	CITATIONS
415	Dexamethasone induces apoptosis in pulmonary arterial smooth muscle cells. <i>Respiratory Research</i> , 2015, 16, 114.	1.4	24
416	Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects. <i>Human Mutation</i> , 2015, 36, 1113-1127.	1.1	185
417	Pulmonary Hypertension Complicating Fibrosing Mediastinitis. <i>Medicine (United States)</i> , 2015, 94, e1800.	0.4	46
418	Non-Invasive Determination of Cardiac Output in Pre-Capillary Pulmonary Hypertension. <i>PLoS ONE</i> , 2015, 10, e0134221.	1.1	10
419	T-Helper 17 Cell Polarization in Pulmonary Arterial Hypertension. <i>Chest</i> , 2015, 147, 1610-1620.	0.4	72
420	Role of Nerve Growth Factor in Development and Persistence of Experimental Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 342-355.	2.5	30
421	Inspiratory muscle function, dynamic hyperinflation and exertional dyspnoea in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2015, 45, 1495-1498.	3.1	37
422	Rare (pulmonary) disease day: "feeding the breath, energy for life!" <i>European Respiratory Journal</i> , 2015, 45, 297-300.	3.1	7
423	Pulmonary Arterial Hypertension in the Southern Hemisphere. <i>Chest</i> , 2015, 147, 495-501.	0.4	54
424	Nasal decongestant exposure in patients with pulmonary arterial hypertension: a pilot study. <i>European Respiratory Journal</i> , 2015, 46, 1211-1214.	3.1	5
425	Chronic thromboembolic pulmonary hypertension. <i>Presse Medicale</i> , 2015, 44, e409-e416.	0.8	26
426	Response to Letter Regarding Article, "Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension" <i>Circulation</i> , 2015, 132, e154.	1.6	3
427	Prognostic value of right ventricular ejection fraction in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2015, 45, 139-149.	3.1	53
428	Development and validation of a novel risk score for asthma exacerbations: The risk score for exacerbations. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 1457-1464.e4.	1.5	88
429	Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). <i>European Respiratory Journal</i> , 2015, 45, 1303-1313.	3.1	174
430	Perceived 10-year change in respiratory health: Reliability and predictive ability. <i>Respiratory Medicine</i> , 2015, 109, 188-199.	1.3	6
431	Nebivolol for Improving Endothelial Dysfunction, Pulmonary Vascular Remodeling, and Right Heart Function in Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2015, 65, 668-680.	1.2	119
432	A Critical Appraisal of the Updated 2014 Nice Pulmonary Hypertension Classification System. <i>Canadian Journal of Cardiology</i> , 2015, 31, 367-374.	0.8	15

#	ARTICLE	IF	CITATIONS
433	Management of Scleroderma-Associated Pulmonary Involvement. Current Treatment Options in Rheumatology, 2015, 1, 51-67.	0.6	0
434	Chemotherapy-Induced Pulmonary Hypertension. American Journal of Pathology, 2015, 185, 356-371.	1.9	149
435	Endothelial-to-Mesenchymal Transition in Pulmonary Hypertension. Circulation, 2015, 131, 1006-1018.	1.6	441
436	Palliative Potts shunt for the treatment of children with drug-refractory pulmonary arterial hypertension: updated data from the first 24 patients. European Journal of Cardio-thoracic Surgery, 2015, 47, e105-e110.	0.6	124
437	Usefulness of Cardiovascular Magnetic Resonance Indices to Rule In or Rule Out Precapillary Pulmonary Hypertension. Canadian Journal of Cardiology, 2015, 31, 1469-1476.	0.8	10
438	Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the Phase III PATENT-1 study. Journal of Heart and Lung Transplantation, 2015, 34, 338-347.	0.3	10
439	Relation between left ventricular ejection time and pulmonary hemodynamics in pulmonary hypertension. International Journal of Cardiology, 2015, 184, 763-765.	0.8	3
440	Epidemiology and Disease Classification of Pulmonary Hypertension. Respiratory Medicine, 2015, , 21-35.	0.1	1
441	Mitomycin-Induced Pulmonary Veno-Occlusive Disease. Circulation, 2015, 132, 834-847.	1.6	103
442	New Molecular Targets of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension. Chest, 2015, 147, 529-537.	0.4	140
443	Pulmonary microvascular lesions regress in reperfused chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2015, 34, 457-467.	0.3	34
444	Systolic and Mean Pulmonary Artery Pressures. Chest, 2015, 147, 943-950.	0.4	38
445	The ambition of the European Respiratory Journal: chapter 3. European Respiratory Journal, 2015, 45, 1-6.	3.1	11
446	Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. European Journal of Internal Medicine, 2015, 26, 545-553.	1.0	371
447	Oral vasopressin receptor antagonist tolvaptan in right heart failure due to pulmonary hypertension. European Respiratory Journal, 2015, 46, 283-286.	3.1	8
448	Management of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2015, 65, 1976-1997.	1.2	296
449	Right ventricular reserve in a piglet model of chronic pulmonary hypertension. European Respiratory Journal, 2015, 45, 709-717.	3.1	38
450	Leptin signalling system as a target for pulmonary arterial hypertension therapy. European Respiratory Journal, 2015, 45, 1066-1080.	3.1	62

#	ARTICLE	IF	CITATIONS
451	Validation of two predictive models for survival in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2015, 46, 152-164.	3.1	82
452	Pulmonary embolism: An update. <i>Presse Medicale</i> , 2015, 44, e373-e376.	0.8	1
453	Proinflammatory Signature of the Dysfunctional Endothelium in Pulmonary Hypertension. Role of the Macrophage Migration Inhibitory Factor/CD74 Complex. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 983-997.	2.5	144
454	Criteria for diagnosis of exercise pulmonary hypertension. <i>European Respiratory Journal</i> , 2015, 46, 728-737.	3.1	213
455	New pharmacotherapy options for pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2113-2131.	0.9	20
456	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. <i>European Respiratory Journal</i> , 2015, 46, 903-975.	3.1	2,415
457	GINA 2015: the latest iteration of a magnificent journey. <i>European Respiratory Journal</i> , 2015, 46, 579-582.	3.1	16
458	Telomere Maintenance Is a Critical Determinant in the Physiopathology of Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1942-1943.	1.2	9
459	Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. <i>European Respiratory Journal</i> , 2015, 46, 1721-1731.	3.1	80
460	Clinical Pharmacology of Endothelin Receptor Antagonists Used in the Treatment of Pulmonary Arterial Hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 13-26.	1.0	27
461	Early detection of pulmonary arterial hypertension. <i>Nature Reviews Cardiology</i> , 2015, 12, 143-155.	6.1	110
462	Inactivation of p53 Is Sufficient to Induce Development of Pulmonary Hypertension in Rats. <i>PLoS ONE</i> , 2015, 10, e0131940.	1.1	40
463	Pulmonary Hypertension in Orphan Lung Diseases. , 2015, , 529-539.		1
464	Hematopoietic Stem Cells and Chronic Hypoxia-Induced Pulmonary Vascular Remodelling. <i>Pancreatic Islet Biology</i> , 2015, , 241-256.	0.1	0
465	Key Role of the Endothelial TGF- $\beta$ 2/ALK1/Endoglin Signaling Pathway in Humans and Rodents Pulmonary Hypertension. <i>PLoS ONE</i> , 2014, 9, e100310.	1.1	83
466	Cooperation between human fibrocytes and endothelial colony-forming cells increases angiogenesis via the CXCR4 pathway. <i>Thrombosis and Haemostasis</i> , 2014, 112, 1002-1013.	1.8	30
467	Increased Pericyte Coverage Mediated by Endothelial-Derived Fibroblast Growth Factor-2 and Interleukin-6 Is a Source of Smooth Muscle-Like Cells in Pulmonary Hypertension. <i>Circulation</i> , 2014, 129, 1586-1597.	1.6	178
468	Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2014, 43, 1195-1198.	3.1	23

#	ARTICLE	IF	CITATIONS
469	Pulmonary arterial hypertension in familial hemiplegic migraine with ATP1A2 channelopathy. <i>European Respiratory Journal</i> , 2014, 43, 641-643.	3.1	11
470	Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with <i>EIF2AK4</i> mutations. <i>European Respiratory Journal</i> , 2014, 44, 1069-1072.	3.1	43
471	Protein Changes Contributing to Right Ventricular Cardiomyocyte Diastolic Dysfunction in Pulmonary Arterial Hypertension. <i>Journal of the American Heart Association</i> , 2014, 3, e000716.	1.6	65
472	Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. <i>European Respiratory Journal</i> , 2014, 43, 1691-1697.	3.1	319
473	Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension. <i>Circulation</i> , 2014, 130, 2189-2208.	1.6	278
474	The ambition of the <i>European Respiratory Journal</i> : chapter 2. <i>European Respiratory Journal</i> , 2014, 43, 1-2.	3.1	6
475	<i>KCNK3</i> : new gene target for pulmonary hypertension?. <i>Expert Review of Respiratory Medicine</i> , 2014, 8, 385-387.	1.0	20
476	Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature. <i>European Respiratory Journal</i> , 2014, 44, 1275-1288.	3.1	201
477	Evidence for the Involvement of Type I Interferon in Pulmonary Arterial Hypertension. <i>Circulation Research</i> , 2014, 114, 677-688.	2.0	124
478	Translational research in pulmonary hypertension: challenge and opportunity. <i>European Respiratory Journal</i> , 2014, 43, 325-328.	3.1	1
479	The role of combination therapy in managing pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2014, 23, 469-475.	3.0	44
480	Asthma: still a promising future?. <i>European Respiratory Review</i> , 2014, 23, 405-407.	3.0	25
481	Pulmonary arterial hypertension in patients treated with interferon. <i>European Respiratory Journal</i> , 2014, 44, 1627-1634.	3.1	80
482	Chronic thromboembolic pulmonary hypertension complicating long-term cyproterone acetate therapy. <i>European Respiratory Review</i> , 2014, 23, 260-263.	3.0	3
483	Inflammation in pulmonary hypertension: what we know and what we could logically and safely target first. <i>Drug Discovery Today</i> , 2014, 19, 1251-1256.	3.2	48
484	Right ventricular plasticity in a porcine model of chronic pressure overload. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 194-202.	0.3	20
485	<i>EIF2AK4</i> mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. <i>Nature Genetics</i> , 2014, 46, 65-69.	9.4	351
486	Targeted therapies in pulmonary arterial hypertension. , 2014, 141, 172-191.		171

#	ARTICLE	IF	CITATIONS
487	Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2014, 43, 915-917.	3.1	111
488	The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. <i>European Respiratory Journal</i> , 2014, 44, 239-241.	3.1	70
489	Omalizumab in Asthma: An Update on Recent Developments. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 525-536.e1.	2.0	179
490	Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. <i>New England Journal of Medicine</i> , 2014, 371, 1198-1207.	13.9	1,807
491	Mononeuritis multiplex predicts the need for immunosuppressive or immunomodulatory drugs for EGPA, PAN and MPA patients without poor-prognosis factors. <i>Autoimmunity Reviews</i> , 2014, 13, 945-953.	2.5	48
492	Contractile Dysfunction of Left Ventricular Cardiomyocytes in Patients With Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2014, 64, 28-37.	1.2	82
493	Update in systemic sclerosis-associated pulmonary arterial hypertension. <i>Presse Medicale</i> , 2014, 43, e293-e304.	0.8	28
494	Inflammation and Immunity in the Pathogenesis of Pulmonary Arterial Hypertension. <i>Circulation Research</i> , 2014, 115, 165-175.	2.0	708
495	N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats. <i>Respiratory Research</i> , 2014, 15, 65.	1.4	38
496	Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group. <i>Presse Medicale</i> , 2014, 43, e345-e363.	0.8	42
497	Enhanced glucocorticoid-induced leucine zipper in dendritic cells induces allergen-specific regulatory CD4 <sup>+</sup> T cells in respiratory allergies. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 624-631.	2.7	17
498	Immune Dysregulation and Endothelial Dysfunction in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2014, 129, 1332-1340.	1.6	141
499	Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension. <i>Biochemical and Biophysical Research Communications</i> , 2014, 451, 8-14.	1.0	69
500	CYP2C9, SLCO1B1, SLCO1B3, and ABCB11 Polymorphisms in Patients With Bosentan-Induced Liver Toxicity. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 583-585.	2.3	13
501	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2014, 35, 3033-3080.	1.0	2,591
502	Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: Data from the French pulmonary hypertension registry. <i>International Journal of Cardiology</i> , 2014, 172, 561-567.	0.8	28
503	Integrated care pathways for airway diseases (AIRWAYS-ICPs). <i>European Respiratory Journal</i> , 2014, 44, 304-323.	3.1	154
504	The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension. <i>Therapeutic Advances in Respiratory Disease</i> , 2014, 8, 84-92.	1.0	7



#	ARTICLE	IF	CITATIONS
505	An Official American Thoracic Society Statement: Pulmonary Hypertension Phenotypes. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 345-355.	2.5	70
506	Systematic Analysis of Blood Cell Transcriptome in End-Stage Chronic Respiratory Diseases. PLoS ONE, 2014, 9, e109291.	1.1	28
507	Acute Right Heart Failure in Pulmonary Hypertension. , 2014, , 261-275.		0
508	Omaliuzumab in the treatment of severe allergic (IgE-mediated) asthma: an update on recent developments. Clinical and Translational Allergy, 2013, 3, O12.	1.4	0
509	A Novel Channelopathy in Pulmonary Arterial Hypertension. New England Journal of Medicine, 2013, 369, 351-361.	13.9	412
510	Riociguat for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2013, 369, 330-340.	13.9	1,120
511	Evidence of endogenous volatile organic compounds as biomarkers of diseases in alveolar breath. Annales Pharmaceutiques Francaises, 2013, 71, 203-215.	0.4	19
512	Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1193-1205.	1.5	22
513	Novel Medical Therapies for Pulmonary Arterial Hypertension. Clinics in Chest Medicine, 2013, 34, 867-880.	0.8	9
514	Survival and Prognostic Factors in Systemic Sclerosis-associated Pulmonary Hypertension: A Systematic Review and Meta-analysis. Arthritis and Rheumatism, 2013, 65, 2412-2423.	6.7	205
515	L5. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Presse Medicale, 2013, 42, 507-510.	0.8	28
516	Reply: The Renin-Angiotensin System in Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 1139-1140.	2.5	0
517	Genetics and Genomics of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2013, 62, D13-D21.	1.2	367
518	Recommendations for Screening and Detection of Connective Tissue Disease-associated Pulmonary Arterial Hypertension. Arthritis and Rheumatism, 2013, 65, 3194-3201.	6.7	175
519	Drugs induced pulmonary arterial hypertension. Presse Medicale, 2013, 42, e303-e310.	0.8	28
520	An Update on Medical Therapy for Pulmonary Arterial Hypertension. Current Hypertension Reports, 2013, 15, 614-622.	1.5	19
521	Pulmonary arterial hypertension. Orphanet Journal of Rare Diseases, 2013, 8, 97.	1.2	226
522	Strong linear relationship between heart rate and mean pulmonary artery pressure in exercising patients with severe precapillary pulmonary hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 305, H769-H777.	1.5	27

#	ARTICLE	IF	CITATIONS
523	Chronic thromboembolic pulmonary hypertension: advances from bench to patient management. <i>European Respiratory Journal</i> , 2013, 41, 8-9.	3.1	23
524	Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D51-D59.	1.2	432
525	A Proof of Concept for the Detection and Classification of Pulmonary Arterial Hypertension through Breath Analysis with a Sensor Array. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 756-759.	2.5	40
526	The Role of Inflammation and Autoimmunity in the Pathophysiology of Pulmonary Arterial Hypertension. <i>Clinical Reviews in Allergy and Immunology</i> , 2013, 44, 31-38.	2.9	85
527	Small platelet microparticle levels are increased in pulmonary arterial hypertension. <i>European Journal of Clinical Investigation</i> , 2013, 43, 64-71.	1.7	31
528	Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension. <i>Nature Genetics</i> , 2013, 45, 518-521.	9.4	93
529	Does Omalizumab Make a Difference to the Real-life Treatment of Asthma Exacerbations?. <i>Chest</i> , 2013, 143, 398-405.	0.4	87
530	Dynamic respiratory mechanics and exertional dyspnoea in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2013, 41, 578-587.	3.1	91
531	Thorax Innovation (TORINO). <i>Presse Medicale</i> , 2013, 42, e301-e302.	0.8	0
532	A Proof-of-Concept, Randomized, Controlled Trial of Omalizumab in Patients With Severe, Difficult-to-Control, Nonatopic Asthma. <i>Chest</i> , 2013, 144, 411-419.	0.4	176
533	Pathogenesis of pulmonary arterial hypertension: lessons from cancer. <i>European Respiratory Review</i> , 2013, 22, 543-551.	3.0	172
534	New perspectives in long-term outcomes in clinical trials of pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2013, 22, 495-502.	3.0	13
535	Cytotoxic Cells and Granulysin in Pulmonary Arterial Hypertension and Pulmonary Veno-occlusive Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 189-196.	2.5	54
536	The ambition of the <i>European Respiratory Journal</i> . <i>European Respiratory Journal</i> , 2013, 41, 1-2.	3.1	9
537	Inflammatory Mechanisms in HIV-Associated Pulmonary Arterial Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2013, 34, 645-653.	0.8	16
538	Idiopathic Pulmonary Arterial Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2013, 34, 560-567.	0.8	11
539	Cellular microparticles in the pathogenesis of pulmonary hypertension. <i>European Respiratory Journal</i> , 2013, 42, 272-279.	3.1	51
540	Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. <i>European Respiratory Journal</i> , 2013, 41, 96-103.	3.1	92

#	ARTICLE	IF	CITATIONS
541	Non-invasive indices of right ventricular function are markers of ventricular-arterial coupling rather than ventricular contractility: insights from a porcine model of chronic pressure overload. <i>European Heart Journal Cardiovascular Imaging</i> , 2013, 14, 1140-1149.	0.5	74
542	Drug-induced pulmonary arterial hypertension: a recent outbreak. <i>European Respiratory Review</i> , 2013, 22, 244-250.	3.0	81
543	Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1940-1946.	0.5	128
544	Out-of-Proportion Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction. <i>Respiration</i> , 2013, 85, 471-477.	1.2	20
545	Future perspectives on rare pulmonary diseases and rare presentations of common disorders. <i>European Respiratory Review</i> , 2013, 22, 199-201.	3.0	4
546	Renal Replacement Therapy in Patients with Severe Precapillary Pulmonary Hypertension with Acute Right Heart Failure. <i>Respiration</i> , 2013, 85, 464-470.	1.2	15
547	Tyrosine Kinase Inhibitors in Pulmonary Arterial Hypertension: A Double-Edge Sword?. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2013, 34, 714-724.	0.8	54
548	Current Challenges in Pulmonary Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2013, 34, 549-550.	0.8	1
549	Right Ventricular Diastolic Impairment in Patients With Pulmonary Arterial Hypertension. <i>Circulation</i> , 2013, 128, 2016-2025.	1.6	294
550	Anti-interleukin-5 therapy in severe asthma. <i>European Respiratory Review</i> , 2013, 22, 251-257.	3.0	107
551	Impression, Sunset. <i>Circulation</i> , 2013, 127, 1098-1100.	1.6	25
552	Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. <i>European Respiratory Journal</i> , 2013, 41, 1302-1307.	3.1	131
553	Therapeutic Efficacy of AAV1.SERCA2a in Monocrotaline-Induced Pulmonary Arterial Hypertension. <i>Circulation</i> , 2013, 128, 512-523.	1.6	97
554	Estimating Right Ventricular Stroke Work and the Pulsatile Work Fraction in Pulmonary Hypertension. <i>Chest</i> , 2013, 143, 1343-1350.	0.4	34
555	High Occurrence of Hypoxemic Sleep Respiratory Disorders in Precapillary Pulmonary Hypertension and Mechanisms. <i>Chest</i> , 2013, 143, 47-55.	0.4	82
556	Left Ventricular Ejection Time in Acute Heart Failure Complicating Precapillary Pulmonary Hypertension. <i>Chest</i> , 2013, 144, 1512-1520.	0.4	26
557	Nuclear Factor $\kappa$ -B Is Activated in the Pulmonary Vessels of Patients with End-Stage Idiopathic Pulmonary Arterial Hypertension. <i>PLoS ONE</i> , 2013, 8, e75415.	1.1	77
558	Endothelin Receptor Antagonists. <i>Handbook of Experimental Pharmacology</i> , 2013, 218, 199-227.	0.9	17

#	ARTICLE	IF	CITATIONS
559	Endothelin Receptor Antagonists. Handbook of Experimental Pharmacology, 2013, , 199-227.	0.9	11
560	Temporal Asthma Patterns Using Repeated Questionnaires over 13 Years in a Large French Cohort of Women. PLoS ONE, 2013, 8, e65090.	1.1	11
561	The Beneficial Effect of Suramin on Monocrotaline-Induced Pulmonary Hypertension in Rats. PLoS ONE, 2013, 8, e77073.	1.1	11
562	Copper Dependence of Angioproliferation in Pulmonary Arterial Hypertension in Rats and Humans. American Journal of Respiratory Cell and Molecular Biology, 2012, 46, 582-591.	1.4	46
563	Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients. European Respiratory Journal, 2012, 40, 630-640.	3.1	80
564	The association between resting and mild-to-moderate exercise pulmonary artery pressure. European Respiratory Journal, 2012, 39, 313-318.	3.1	21
565	ERS publications: the flagship and the fleet. European Respiratory Journal, 2012, 40, 535-537.	3.1	11
566	A critical analysis of survival in pulmonary arterial hypertension. European Respiratory Review, 2012, 21, 218-222.	3.0	39
567	Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. European Respiratory Journal, 2012, 40, 881-885.	3.1	221
568	The fifth world symposium on pulmonary hypertension will REVEAL the impact of registries. European Respiratory Review, 2012, 21, 4-5.	3.0	5
569	IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction. Annals of the Rheumatic Diseases, 2012, 71, 596-605.	0.5	41
570	Pulmonary hypertension associated with benfluorex exposure. European Respiratory Journal, 2012, 40, 1164-1172.	3.1	75
571	Survivor bias and risk assessment. European Respiratory Journal, 2012, 40, 530-532.	3.1	49
572	Pulmonary arterial hypertension: bridging the present to the future. European Respiratory Review, 2012, 21, 267-270.	3.0	12
573	Circulating fibrocytes and pulmonary arterial hypertension. European Respiratory Journal, 2012, 39, 210-212.	3.1	8
574	Ventilation/perfusion lung scan in pulmonary veno-occlusive disease. European Respiratory Journal, 2012, 40, 75-83.	3.1	53
575	Plasma Levels of High-Density Lipoprotein Cholesterol Are Not Associated with Survival in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 107-107.	2.5	11
576	A Critical Role for p130 <sup>Cas</sup> in the Progression of Pulmonary Hypertension in Humans and Rodents. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 666-676.	2.5	85

#	ARTICLE	IF	CITATIONS
577	Progress in Pulmonary Arterial Hypertension Pathology: Relighting a Torch Inside the Tunnel. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 210-212.	2.5	24
578	Human Immunodeficiency Virus Signature Sequences Are Associated with Pulmonary Hypertension. AIDS Research and Human Retroviruses, 2012, 28, 607-618.	0.5	50
579	Early detection and management of pulmonary arterial hypertension. European Respiratory Review, 2012, 21, 306-312.	3.0	94
580	Genetics of Pulmonary Arterial Hypertension and the Concept of Heritable Pulmonary Arterial Hypertension. Progress in Respiratory Research, 2012, , 65-75.	0.1	0
581	Idiopathic Pulmonary Arterial Hypertension and Its Prognosis in the Modern Management Era in Developed and Developing Countries. Progress in Respiratory Research, 2012, , 85-93.	0.1	11
582	Pulmonary Arterial Hypertension and HIV and Other Viral Infections. Progress in Respiratory Research, 2012, , 105-112.	0.1	2
583	EBUS-TBNA in the differential diagnosis of pulmonary artery sarcoma and thromboembolism: Figure 1â€“. European Respiratory Journal, 2012, 39, 1549-1550.	3.1	13
584	Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma. European Respiratory Journal, 2012, 39, 1405-1414.	3.1	90
585	Mediastinal Fibrosis Mimicking Proximal Chronic Thromboembolic Disease. Circulation, 2012, 125, 2045-2047.	1.6	5
586	You say goodbye, and I say hello!. European Respiratory Review, 2012, 21, 265-266.	3.0	5
587	Drug- and Toxin-Induced Pulmonary Arterial Hypertension. Progress in Respiratory Research, 2012, , 76-84.	0.1	0
588	Severe Pulmonary Hypertension Associated With Emphysema. Chest, 2012, 142, 1654-1658.	0.4	19
589	Independent Association of Urinary F2-Isoprostanes With Survival in Pulmonary Arterial Hypertension. Chest, 2012, 142, 869-876.	0.4	50
590	Pulmonary Veno-Occlusive Disease. Progress in Respiratory Research, 2012, , 149-160.	0.1	0
591	Riociguat for the Treatment of Pulmonary Arterial Hypertension: A Randomized, Double-Blind, Placebo-Controlled Study (PATENT-1). Chest, 2012, 142, 1027A.	0.4	21
592	Inflammation in Pulmonary Arterial Hypertension. Chest, 2012, 141, 210-221.	0.4	333
593	Pulmonary Langerhans Cell Histiocytosis-Associated Pulmonary Hypertension. Chest, 2012, 142, 1150-1157.	0.4	104
594	Serotonin 5-HT2B receptors are required for bone-marrow contribution to pulmonary arterial hypertension. Blood, 2012, 119, 1772-1780.	0.6	89

#	ARTICLE	IF	CITATIONS
595	Dysregulated Renin-Angiotensin-Aldosterone System Contributes to Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 780-789.	2.5	309
596	Potts Shunt in Children With Idiopathic Pulmonary Arterial Hypertension: Long-Term Results. <i>Annals of Thoracic Surgery</i> , 2012, 94, 817-824.	0.7	116
597	Immunologic Therapeutic Interventions in Asthma. <i>Clinics in Chest Medicine</i> , 2012, 33, 585-597.	0.8	6
598	Global effort against rare and orphan diseases. <i>European Respiratory Review</i> , 2012, 21, 171-172.	3.0	12
599	TGF $\beta$ 2 receptor gene variants in systemic sclerosis-related pulmonary arterial hypertension: results from a multicentre EUSTAR study of European Caucasian patients. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1900-1903.	0.5	18
600	Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2012, 40, 895-904.	3.1	110
601	Pulmonary Lymphoid Neogenesis in Idiopathic Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 311-321.	2.5	249
602	Introduction: Devising a Prognostic Score for Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2012, 110, S1-S2.	0.7	2
603	Pulmonary hypertension complicating sarcoidosis. <i>Presse Medicale</i> , 2012, 41, e303-e316.	0.8	30
604	Everything you always wanted to know about sarcoidosis but were afraid to ask. <i>Presse Medicale</i> , 2012, 41, e273-e274.	0.8	2
605	Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 150-158.	0.3	91
606	Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension. <i>Arthritis and Rheumatism</i> , 2012, 64, 2995-3005.	6.7	108
607	Clinical Year in Review IV. <i>Proceedings of the American Thoracic Society</i> , 2012, 9, 204-209.	3.5	3
608	Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 1049-1062.	1.5	486
609	Pre-implantation genetic diagnosis in pulmonary arterial hypertension due to <i>BMPR2</i> mutation: Figure 1. <i>European Respiratory Journal</i> , 2012, 39, 1534-1535.	3.1	35
610	The study of risk in pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2012, 21, 234-238.	3.0	15
611	Severe Chronic Allergic (and Related) Diseases: A Uniform Approach - A MeDALL - GA&sup>2&lt;/sup>LEN - ARIA Position Paper. <i>International Archives of Allergy and Immunology</i> , 2012, 158, 216-231.	0.9	83
612	A study of magnesium deficiency in human and experimental pulmonary hypertension. <i>Magnesium Research</i> , 2012, 25, 21-27.	0.4	2

#	ARTICLE	IF	CITATIONS
613	Development of prognostic tools in pulmonary arterial hypertension: Lessons from modern day registries. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1049-1060.	1.8	14
614	Could the Cochin risk prediction score be applied in daily practice to predict pulmonary hypertension in systemic sclerosis? Comment on the article by Meune et al. <i>Arthritis and Rheumatism</i> , 2012, 64, 2051-2052.	6.7	2
615	Pulmonary Arterial Hypertension in Patients Treated by Dasatinib. <i>Circulation</i> , 2012, 125, 2128-2137.	1.6	548
616	<i>ACVRL1</i> germinal mosaic with two mutant alleles in hereditary hemorrhagic telangiectasia associated with pulmonary arterial hypertension. <i>Clinical Genetics</i> , 2012, 82, 173-179.	1.0	26
617	Pulmonary hypertension associated with sarcoidosis. , 2012, , 166-181.		1
618	Inflammation in Pulmonary Arterial Hypertension. , 2012, , 213-229.		1
619	Pulmonary veno-occlusive disease and pulmonary capillary haemangiomas. , 2012, , 182-193.		0
620	Pulmonary hypertension in pulmonary Langerhans cell histiocytosis. , 2012, , 161-165.		0
621	Pulmonary veno-occlusive disease: advances in clinical management and treatments. <i>Expert Review of Respiratory Medicine</i> , 2011, 5, 217-231.	1.0	41
622	Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed. <i>Arthritis Research and Therapy</i> , 2011, 13, 114.	1.6	8
623	Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats. <i>European Respiratory Journal</i> , 2011, 37, 813-822.	3.1	85
624	Diaphragm Muscle Fiber Weakness in Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 1411-1418.	2.5	72
625	Pulmonary veno-occlusive disease: The bête noire of pulmonary hypertension in connective tissue diseases?. <i>Presse Medicale</i> , 2011, 40, e87-e100.	0.8	25
626	Quarterly Medical Review: Pulmonary involvement in systemic diseases. <i>Presse Medicale</i> , 2011, 40, e23-e24.	0.8	0
627	Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1585-1596.	0.9	23
628	Human $\beta$ -Herpesviruses Epstein-Barr Virus and Human Herpesvirus-8 Are Not Detected in the Lungs of Patients With Severe Pulmonary Arterial Hypertension. <i>Chest</i> , 2011, 139, 1310-1316.	0.4	26
629	Pulmonary Hypertension in Patients With Neurofibromatosis Type I. <i>Medicine (United States)</i> , 2011, 90, 201-211.	0.4	60
630	Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2011, 66, 671-678.	2.7	135



#	ARTICLE	IF	CITATIONS
631	Current management approaches to portopulmonary hypertension. <i>International Journal of Clinical Practice</i> , 2011, 65, 11-18.	0.8	19
632	Scleroderma Lung Disease. <i>Clinical Reviews in Allergy and Immunology</i> , 2011, 40, 104-116.	2.9	41
633	Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension. <i>Respiratory Research</i> , 2011, 12, 119.	1.4	67
634	Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. <i>Respiratory Research</i> , 2011, 12, 38.	1.4	58
635	Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. <i>Human Mutation</i> , 2011, 32, 1385-1389.	1.1	152
636	Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: Impact of pulmonary arterial hypertension therapies. <i>Arthritis and Rheumatism</i> , 2011, 63, 2456-2464.	6.7	109
637	Screening for pulmonary arterial hypertension in patients with systemic sclerosis: Clinical characteristics at diagnosis and long-term survival. <i>Arthritis and Rheumatism</i> , 2011, 63, 3522-3530.	6.7	291
638	Autocrine Fibroblast Growth Factor-2 Signaling Contributes to Altered Endothelial Phenotype in Pulmonary Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 45, 311-322.	1.4	125
639	Corrigendum to: Guidelines for the diagnosis and treatment of pulmonary hypertension [European Heart Journal (2009) 30, 2493-2537]. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). <i>European Heart Journal</i> , 2011, 32, 926-926.	1.0	60
640	C-Kit-Positive Cells Accumulate in Remodeled Vessels of Idiopathic Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 116-123.	2.5	176
641	Analysis of the Validation Status of Quality of Life and Functional Disability Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis: Results of a Systematic Literature Analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS). <i>Journal of Rheumatology</i> , 2011, 38, 2419-2427.	1.0	4
642	Treatment of pulmonary arterial hypertension with targeted therapies. <i>Nature Reviews Cardiology</i> , 2011, 8, 526-538.	6.1	125
643	Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic pulmonary hypertension. <i>European Respiratory Journal</i> , 2011, 37, 1392-1399.	3.1	85
644	Effect of different asthma treatments on risk of cold-related exacerbations. <i>European Respiratory Journal</i> , 2011, 38, 584-593.	3.1	35
645	Whistleblowers. <i>European Respiratory Journal</i> , 2011, 38, 510-511.	3.1	8
646	A decade of achievement in pulmonary hypertension. <i>European Respiratory Review</i> , 2011, 20, 215-217.	3.0	14
647	Survival of Chinese Patients With Pulmonary Arterial Hypertension in the Modern Treatment Era. <i>Chest</i> , 2011, 140, 301-309.	0.4	161
648	Pulmonary Arterial Hypertension in a Patient With Cowden Syndrome and Anorexigen Exposure. <i>Chest</i> , 2011, 140, 1066-1068.	0.4	8

#	ARTICLE	IF	CITATIONS
649	Predicting Survival in Pulmonary Arterial Hypertension. <i>Chest</i> , 2011, 139, 1263-1264.	0.4	9
650	Clinical Characteristics and Survival in Systemic Sclerosis-Related Pulmonary Hypertension Associated With Interstitial Lung Disease. <i>Chest</i> , 2011, 140, 1016-1024.	0.4	89
651	Letter by Montani et al Regarding Article, "Elevated Levels of Inflammatory Cytokines Predict Survival in Idiopathic and Familial Pulmonary Arterial Hypertension"; <i>Circulation</i> , 2011, 123, e614; author reply e615.	1.6	7
652	Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 2888-2897.	3.9	83
653	Late Limited Systemic Sclerosis Patient Who Develops Shortness of Breath on Exertion. , 2011, , 127-137.		0
654	Pulmonary hypertension associated with portal hypertension. , 2011, , 245-250.		0
655	Pulmonary hypertension related to appetite suppressants. , 2011, , 236-244.		0
656	HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. <i>Aids</i> , 2010, 24, 67-75.	1.0	149
657	Characterization of Pulmonary Arterial Hypertension Patients Walking More Than 450 m in 6 Min at Diagnosis. <i>Chest</i> , 2010, 137, 1297-1303.	0.4	46
658	Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis?. <i>Chest</i> , 2010, 138, 462-463.	0.4	1
659	Endpoints in pulmonary arterial hypertension: the role of clinical worsening. <i>Current Opinion in Pulmonary Medicine</i> , 2010, 16, S1-S9.	1.2	24
660	Chronic thromboembolic pulmonary hypertension (CTEPH): specific disease characteristics and similarities to idiopathic pulmonary arterial hypertension. <i>Clinical Research in Cardiology Supplements</i> , 2010, 5, 12-15.	2.0	0
661	Endothelin A receptor blockade improves regression of flow-induced pulmonary vasculopathy in piglets. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2010, 140, 677-683.	0.4	7
662	Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. <i>Respiratory Research</i> , 2010, 11, 73.	1.4	81
663	Association of a <i>KCNAS5</i> gene polymorphism with systemic sclerosis-associated pulmonary arterial hypertension in the European Caucasian population. <i>Arthritis and Rheumatism</i> , 2010, 62, 3093-3100.	6.7	49
664	Development and implementation of guidelines in allergic rhinitis "an ARIA-GA<sup>2</sup>LEN paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 1212-1221.	2.7	85
665	Benfluorex and Unexplained Valvular Heart Disease: A Case-Control Study. <i>PLoS ONE</i> , 2010, 5, e10128.	1.1	77
666	Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. <i>Rheumatology</i> , 2010, 49, 490-500.	0.9	91

#	ARTICLE	IF	CITATIONS
667	Pharmacokinetic evaluation of continuous intravenous epoprostenol. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 1587-1598.	1.5	15
668	Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. <i>Rheumatology</i> , 2010, 49, 940-944.	0.9	53
669	Severe pulmonary hypertension in histiocytosis X: long-term improvement with bosentan. <i>European Respiratory Journal</i> , 2010, 36, 202-204.	3.1	29
670	Noncardiothoracic nonobstetric surgery in mild-to-moderate pulmonary hypertension. <i>European Respiratory Journal</i> , 2010, 35, 1294-1302.	3.1	119
671	Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. <i>European Respiratory Journal</i> , 2010, 35, 105-111.	3.1	398
672	Antifibroblast antibodies from systemic sclerosis patients bind to $\alpha$ 1-enolase and are associated with interstitial lung disease. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 428-433.	0.5	51
673	Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1360-1363.	0.5	34
674	Pulmonary arterial hypertension and the state of limbo. <i>European Respiratory Review</i> , 2010, 19, 264-265.	3.0	0
675	Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2010, 35, 1286-1293.	3.1	226
676	Imatinib inhibits bone marrow-derived c-kit <sup>+</sup> cell mobilisation in hypoxic pulmonary hypertension. <i>European Respiratory Journal</i> , 2010, 36, 1209-1211.	3.1	25
677	Association of pulmonary aspergilloma and allergic bronchopulmonary aspergillosis. <i>European Respiratory Review</i> , 2010, 19, 349-351.	3.0	10
678	Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2010, 36, 549-555.	3.1	582
679	Echocardiography as an Outcome Measure in Scleroderma-related Pulmonary Arterial Hypertension: A Systematic Literature Analysis by the EPOSS Group. <i>Journal of Rheumatology</i> , 2010, 37, 105-115.	1.0	37
680	Measuring asthma control: a comparison of three classification systems. <i>European Respiratory Journal</i> , 2010, 36, 269-276.	3.1	80
681	Prioritised research agenda for prevention and control of chronic respiratory diseases. <i>European Respiratory Journal</i> , 2010, 36, 995-1001.	3.1	125
682	Update on the European Respiratory Review. <i>European Respiratory Journal</i> , 2010, 36, 993-994.	3.1	4
683	Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology. <i>European Respiratory Review</i> , 2010, 19, 59-63.	3.0	127
684	Beyond arterial remodelling: pulmonary venous and cardiac involvement in patients with systemic sclerosis-associated pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2010, 35, 6-8.	3.1	31

#	ARTICLE	IF	CITATIONS
685	The changing face of respiratory physiology: 20 years of progress within the ERS: Clinical Physiology and Integrative Biology Assembly contribution to the celebration of 20 years of the ERS. <i>European Respiratory Journal</i> , 2010, 35, 945-948.	3.1	1
686	Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. <i>European Heart Journal</i> , 2010, 31, 1898-1907.	1.0	218
687	Strategic Plan for Lung Vascular Research. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 1554-1562.	2.5	73
688	Vasodilators in Patients with Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 202-203.	2.5	12
689	Systemic Sclerosis-associated Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 1285-1293.	2.5	91
690	Survival in Schistosomiasis-Associated Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2010, 56, 715-720.	1.2	68
691	Overall asthma control: The relationship between current control and future risk. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 600-608.e6.	1.5	219
692	Clinical Outcomes of Pulmonary Arterial Hypertension in Patients Carrying an <i>ACVRL1</i> ( <i>ALK1</i> ) Mutation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 851-861.	2.5	259
693	Pulmonary veno-occlusive disease: Recent progress and current challenges. <i>Respiratory Medicine</i> , 2010, 104, S23-S32.	1.3	94
694	Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension. <i>Respiratory Medicine</i> , 2010, 104, S74-S80.	1.3	11
695	Omalizumab-induced decrease of FcεRI expression in patients with severe allergic asthma. <i>Respiratory Medicine</i> , 2010, 104, 1608-1617.	1.3	73
696	Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era. <i>Circulation</i> , 2010, 122, 156-163.	1.6	1,264
697	Interactions between rheumatologists and cardio-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, S47-52.	0.4	7
698	Stress Doppler Echocardiography in Relatives of Patients With Idiopathic and Familial Pulmonary Arterial Hypertension. <i>Circulation</i> , 2009, 119, 1747-1757.	1.6	205
699	Cardiopulmonary Manifestations of Hepatosplenic Schistosomiasis. <i>Circulation</i> , 2009, 119, 1518-1523.	1.6	176
700	Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22 $\alpha$ -targeted overexpression of the serotonin transporter. <i>FASEB Journal</i> , 2009, 23, 4135-4147.	0.2	80
701	Fatal rupture of pulmonary arteriovenous malformation in hereditary haemorrhagic telangiectasis and severe PAH. <i>European Respiratory Review</i> , 2009, 18, 42-46.	3.0	23
702	Pulmonary veno-occlusive disease. <i>European Respiratory Journal</i> , 2009, 33, 189-200.	3.1	267

#	ARTICLE	IF	CITATIONS
703	Bone morphogenetic protein signalling in heritable versus idiopathic pulmonary hypertension. <i>European Respiratory Journal</i> , 2009, 34, 1100-1110.	3.1	68
704	Update in Pulmonary Hypertension 2008. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 650-656.	2.5	32
705	Evaluation of Various Empirical Formulas for Estimating Mean Pulmonary Artery Pressure by Using Systolic Pulmonary Artery Pressure in Adults. <i>Chest</i> , 2009, 135, 760-768.	0.4	102
706	Screening for Portopulmonary Hypertension with Transthoracic Echocardiography: Implications for Early Mortality Associated with Liver Transplantation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 378-379.	2.5	2
707	Pulmonary Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2009, 30, 367-368.	0.8	0
708	RhoA and Rho Kinase Activation in Human Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 1151-1158.	2.5	165
709	Idiopathic Pulmonary Arterial Hypertension and Pulmonary Veno-occlusive Disease: Similarities and Differences. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2009, 30, 411-420.	0.8	37
710	Implementing the ESC/ERS pulmonary hypertension guidelines: real-life cases from a national referral centre. <i>European Respiratory Review</i> , 2009, 18, 272-290.	3.0	31
711	Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. <i>European Respiratory Journal</i> , 2009, 34, 1348-1356.	3.1	90
712	The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. <i>Arthritis and Rheumatism</i> , 2009, 60, 1831-1839.	6.7	179
713	Montelukast in guidelines and beyond. <i>Advances in Therapy</i> , 2009, 26, 575-587.	1.3	15
714	Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. <i>Advances in Therapy</i> , 2009, 26, 813-825.	1.3	96
715	Relation between inflammation and symptoms in asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 354-367.	2.7	43
716	Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). <i>European Heart Journal</i> , 2009, 30, 2493-2537.	1.0	3,108
717	Inflammation, Growth Factors, and Pulmonary Vascular Remodeling. <i>Journal of the American College of Cardiology</i> , 2009, 54, S10-S19.	1.2	605
718	The 4th World Symposium on Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, S1-S2.	1.2	66
719	Future Perspectives for the Treatment of Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, S108-S117.	1.2	62
720	Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar. <i>Revista Española De Cardiología (English Ed)</i> , 2009, 62, 1464.e1-1464.e58.	0.4	2

#	ARTICLE	IF	CITATIONS
721	Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. <i>Journal of Clinical Investigation</i> , 2009, 119, 512-523.	3.9	177
722	Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis?. <i>Chest</i> , 2009, 136, 1211-1219.	0.4	117
723	Pulmonary Venoocclusive Disease and Failure of Specific Therapy. <i>Chest</i> , 2009, 136, 1181.	0.4	9
724	Immunosuppressive therapy in lupus and mixed connective tissue disease-associated pulmonary arterial hypertension: A retrospective analysis of twenty-three cases. <i>Arthritis and Rheumatism</i> , 2008, 58, 521-531.	6.7	321
725	Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: A Delphi consensus study with cluster analysis. <i>Arthritis and Rheumatism</i> , 2008, 59, 867-875.	6.7	56
726	Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension. <i>Vascular Pharmacology</i> , 2008, 49, 113-118.	1.0	118
727	Platelet-derived Growth Factor Expression and Function in Idiopathic Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 81-88.	2.5	405
728	Review: Therapeutic advances in pulmonary arterial hypertension. <i>Therapeutic Advances in Respiratory Disease</i> , 2008, 2, 249-265.	1.0	33
729	Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinerAIR-Sclerodermie study. <i>Rheumatology</i> , 2008, 48, 304-308.	0.9	148
730	Pulmonary Hypertension Associated with Myeloproliferative Disorders: A Retrospective Study of Ten Cases. <i>Respiration</i> , 2008, 76, 295-302.	1.2	60
731	Understanding the Role of CD4+CD25 <sup>high</sup> (So-Called Regulatory) T Cells in Idiopathic Pulmonary Arterial Hypertension. <i>Respiration</i> , 2008, 75, 253-256.	1.2	10
732	Mediators involved in HIV-related pulmonary arterial hypertension. <i>Aids</i> , 2008, 22, S41-S47.	1.0	25
733	Pulmonary arterial hypertension masquerading as severe refractory asthma. <i>European Respiratory Journal</i> , 2008, 32, 513-516.	3.1	32
734	Clinical Outcomes of Pulmonary Arterial Hypertension in Carriers of <i>BMPR2</i> Mutation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 1377-1383.	2.5	269
735	Update in Pulmonary Arterial Hypertension 2007. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 574-579.	2.5	45
736	Portopulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 637-643.	2.5	220
737	Identification of Target Antigens of Antifibroblast Antibodies in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 1128-1134.	2.5	112
738	Safety Experience With Bosentan in 146 Children 2-11 Years Old With Pulmonary Arterial Hypertension: Results from the European Postmarketing Surveillance Program. <i>Pediatric Research</i> , 2008, 64, 200-204.	1.1	103

#	ARTICLE	IF	CITATIONS
739	Severe Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 551-552.	2.5	16
740	Biologics in asthma: difficulties and drawbacks. Expert Opinion on Biological Therapy, 2008, 8, 1921-1928.	1.4	12
741	Pulmonary Veno-Occlusive Disease. Medicine (United States), 2008, 87, 220-233.	0.4	295
742	Role of Endothelium-derived CC Chemokine Ligand 2 in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 1041-1047.	2.5	196
743	Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Annals of the Rheumatic Diseases, 2007, 66, 1610-1615.	0.5	80
744	Genes and Pulmonary Arterial Hypertension. Respiration, 2007, 74, 123-132.	1.2	67
745	Pulmonary Arterial Hypertension: A Rare Complication of Primary Sjögren Syndrome. Medicine (United States), 2007, 86, 1078-1081.	0.4	169
746	Endothelin-1/Endothelin-3 Ratio. Chest, 2007, 131, 101-108.	0.4	64
747	Rapid Switch From Intravenous Epoprostenol to Intravenous Treprostinil in Patients With Pulmonary Arterial Hypertension. Journal of Cardiovascular Pharmacology, 2007, 49, 1-5.	0.8	77
748	NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. Respiratory Medicine, 2007, 101, 69-75.	1.3	65
749	POEMS syndrome-related pulmonary hypertension is steroid-responsive. Respiratory Medicine, 2007, 101, 353-355.	1.3	39
750	Intravenous Epoprostenol in Inoperable Chronic Thromboembolic Pulmonary Hypertension. Journal of Heart and Lung Transplantation, 2007, 26, 357-362.	0.3	126
751	Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Human Pathology, 2007, 38, 893-902.	1.1	291
752	Prise en charge diagnostique et thérapeutique de l'hypertension artérielle pulmonaire. Reanimation: Journal De La Societe De Reanimation De Langue Francaise, 2007, 16, 294-301.	0.1	3
753	H4 histamine receptor mediates optimal migration of mast cell precursors to CXCL12. Journal of Allergy and Clinical Immunology, 2007, 120, 827-834.	1.5	95
754	Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 591-604.	2.7	171
755	Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Research and Therapy, 2006, 8, R114.	1.6	106
756	Deleterious Effects of $\beta$ -Blockers on Exercise Capacity and Hemodynamics in Patients With Portopulmonary Hypertension. Gastroenterology, 2006, 130, 120-126.	0.6	277



#	ARTICLE	IF	CITATIONS
757	Bosentan for the treatment of scleroderma. <i>Future Rheumatology</i> , 2006, 1, 549-562.	0.2	1
758	Immunosuppressive Therapy in Connective Tissue Diseases-Associated Pulmonary Arterial Hypertension. <i>Chest</i> , 2006, 130, 182-189.	0.4	316
759	Sildenafil for Pulmonary Hypertension in Pregnancy?. <i>Anesthesiology</i> , 2006, 104, 383-383.	1.3	3
760	Use of Amplatzer Fenestrated Atrial Septal Defect Device in a Child with Familial Pulmonary Hypertension. <i>Pediatric Cardiology</i> , 2006, 27, 759-762.	0.6	19
761	Mutations of the TGF- $\beta$ 2 type II receptor <i>BMPR2</i> in pulmonary arterial hypertension. <i>Human Mutation</i> , 2006, 27, 121-132.	1.1	368
762	<i>BMPR2</i> gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. <i>Human Mutation</i> , 2006, 27, 212-213.	1.1	196
763	The Right Tools at the Right Time. <i>Chest</i> , 2006, 130, 29S-40S.	0.4	13
764	Serotonin Transporter Polymorphisms in Familial and Idiopathic Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 798-802.	2.5	83
765	Medical Therapies for Chronic Thromboembolic Pulmonary Hypertension: An Evolving Treatment Paradigm. <i>Proceedings of the American Thoracic Society</i> , 2006, 3, 594-600.	3.5	90
766	Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. <i>European Heart Journal</i> , 2006, 27, 589-595.	1.0	272
767	Angiotensin/Tie2 Pathway Influences Smooth Muscle Hyperplasia in Idiopathic Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 1025-1033.	2.5	106
768	The Need for National Registries in Rare Diseases. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 228a-229.	2.5	1
769	Incidence and Prevalence of Chronic Thromboembolic Pulmonary Hypertension: From Acute to Chronic Pulmonary Embolism. <i>Proceedings of the American Thoracic Society</i> , 2006, 3, 564-567.	3.5	126
770	Cross Talk Between Endothelial and Smooth Muscle Cells in Pulmonary Hypertension. <i>Circulation</i> , 2006, 113, 1857-1864.	1.6	257
771	Current understanding of the role of bosentan in inoperable chronic thromboembolic pulmonary hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1133-1138.	0.9	2
772	Pulmonary Arterial Hypertension in France. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 1023-1030.	2.5	1,736
773	Pulmonary arterial hypertension in ANCA-associated vasculitis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2006, 23, 223-8.	0.2	22
774	New Formula for Predicting Mean Pulmonary Artery Pressure. <i>Chest</i> , 2005, 128, 467.	0.4	4

#	ARTICLE	IF	CITATIONS
775	Pulmonary Endothelin-1 Clearance in Human Pulmonary Arterial Hypertension. <i>Chest</i> , 2005, 128, 622S.	0.4	8
776	Serotonin Transporter and Receptors in Various Forms of Human Pulmonary Hypertension. <i>Chest</i> , 2005, 128, 552S-553S.	0.4	17
777	Clinical Challenges in Pulmonary Hypertension. <i>Chest</i> , 2005, 128, 622S-628S.	0.4	23
778	Severe Pulmonary Hypertension during Pregnancy. <i>Anesthesiology</i> , 2005, 102, 1133-1137.	1.3	483
779	Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France. <i>Aids</i> , 2005, 19, 1239-1240.	1.0	29
780	Cirrhotic rats with bacterial translocation have higher incidence and severity of hepatopulmonary syndrome. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 1538-1544.	1.4	57
781	Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study. <i>Arthritis and Rheumatism</i> , 2005, 52, 3792-3800.	6.7	656
782	New chemokine targets for asthma therapy. <i>Current Allergy and Asthma Reports</i> , 2005, 5, 155-160.	2.4	64
783	Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension. <i>Circulation</i> , 2005, 111, 3105-3111.	1.6	1,040
784	Current Insights on the Pathogenesis of Pulmonary Arterial Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2005, 26, 355-364.	0.8	36
785	Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases. <i>Nature Clinical Practice Rheumatology</i> , 2005, 1, 93-101.	3.2	16
786	Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease. <i>European Respiratory Journal</i> , 2005, 26, 969-972.	3.1	46
787	Asthma management: Are GINA guidelines appropriate for daily clinical practice?. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2005, 14, 294-302.	2.5	14
788	Bosentan for the Treatment of Human Immunodeficiency Virus-associated Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 1212-1217.	2.5	238
789	<b>Pulmonary Hypertension:</b> CT of the Chest in Pulmonary Venocclusive Disease. <i>American Journal of Roentgenology</i> , 2004, 183, 65-70.	1.0	234
790	Ciclesonide: a novel inhaled corticosteroid. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 1349-1360.	1.9	23
791	Sildenafil for Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 169, 6-7.	2.5	22
792	New Formula for Predicting Mean Pulmonary Artery Pressure Using Systolic Pulmonary Artery Pressure. <i>Chest</i> , 2004, 126, 1313-1317.	0.4	923

#	ARTICLE	IF	CITATIONS
793	Serotonin-Induced Smooth Muscle Hyperplasia in Various Forms of Human Pulmonary Hypertension. <i>Circulation Research</i> , 2004, 94, 1263-1270.	2.0	187
794	Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. <i>European Heart Journal</i> , 2004, 25, 2243-2278.	1.0	903
795	Cellular and molecular pathobiology of pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2004, 43, S13-S24.	1.2	1,322
796	Pathologic assessment of vasculopathies in pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2004, 43, S25-S32.	1.2	609
797	Treatment of Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2004, 351, 1425-1436.	13.9	1,627
798	The CX3C chemokine fractalkine in allergic asthma and rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 112, 1139-1146.	1.5	82
799	Bronchial immunoglobulin E production in intrinsic asthma. <i>Revue Francaise D'allergologie Et D'immunologie Clinique</i> , 2003, 43, 229-231.	0.1	1
800	An Extreme Consequence of Splenectomy in Dehydrated Hereditary Stomatocytosis: Gradual Thromboembolic Pulmonary Hypertension and Lung Heart Transplantation. <i>Hemoglobin</i> , 2003, 27, 139-147.	0.4	59
801	Prognostic Factors for Survival in Human Immunodeficiency Virus-associated Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 167, 1433-1439.	2.5	295
802	Pathology and aspects of pathogenesis in pulmonary arterial hypertension. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2003, 20, 9-19.	0.2	24
803	Pulmonary Artery Pressure-Flow Relations after Prostacyclin in Primary Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 338-340.	2.5	94
804	Chemokine RANTES in Severe Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 534-539.	2.5	239
805	Hyperplasia of Pulmonary Artery Smooth Muscle Cells Is Causally Related to Overexpression of the Serotonin Transporter in Primary Pulmonary Hypertension. <i>Chest</i> , 2002, 121, 97S-98S.	0.4	32
806	Prevention of Gram-Negative Translocation Reduces the Severity of Hepatopulmonary Syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 166, 514-517.	2.5	179
807	CX3C Chemokine Fractalkine in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 1419-1425.	2.5	247
808	Pulmonary Arterial Hypertension: Thin-Section CT Predictors of Epoprostenol Therapy Failure. <i>Radiology</i> , 2002, 222, 782-788.	3.6	79
809	Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. <i>Journal of the American College of Cardiology</i> , 2002, 39, 1496-1502.	1.2	584
810	Long-term intravenous epoprostenol infusion in primary pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2002, 40, 780-788.	1.2	1,290

#	ARTICLE	IF	CITATIONS
811	Mutations de gènes codant pour des récepteurs du TGF-β <sup>2</sup> (BMPR-2 et ALK-1) dans les hypertensions artérielles pulmonaires primitives. <i>Société De Biologie Journal</i> , 2002, 196, 53-58.	0.3	14
812	Primary pulmonary hypertension: Current therapy. <i>Progress in Cardiovascular Diseases</i> , 2002, 45, 115-128.	1.6	54
813	Severe pulmonary arterial hypertension in type 1 glycogen storage disease. <i>European Journal of Pediatrics</i> , 2002, 161, S93-S96.	1.3	18
814	Severe pulmonary arterial hypertension in type 1 glycogen storage disease. <i>European Journal of Pediatrics</i> , 2002, 161, S93-S96.	1.3	30
815	Polymorphisme du gène codant pour le transporteur de la sérotonine et hypertension artérielle pulmonaire. <i>Medicine/Sciences</i> , 2002, 18, 395-397.	0.0	0
816	Local expression of ÷ germline gene transcripts and RNA for the ÷ heavy chain of IgE in the bronchial mucosa in atopic and nonatopic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 107, 686-692.	1.5	161
817	RISK FACTORS FOR PULMONARY ARTERIAL HYPERTENSION. <i>Clinics in Chest Medicine</i> , 2001, 22, 459-475.	0.8	116
818	BMPR2 Haploinsufficiency as the Inherited Molecular Mechanism for Primary Pulmonary Hypertension. <i>American Journal of Human Genetics</i> , 2001, 68, 92-102.	2.6	521
819	PATHOBIOLOGY OF PULMONARY HYPERTENSION. <i>Clinics in Chest Medicine</i> , 2001, 22, 451-458.	0.8	153
820	Clinical and Molecular Genetic Features of Pulmonary Hypertension in Patients with Hereditary Hemorrhagic Telangiectasia. <i>New England Journal of Medicine</i> , 2001, 345, 325-334.	13.9	676
821	Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. <i>Journal of Clinical Investigation</i> , 2001, 108, 1141-1150.	3.9	446
822	Severe Pulmonary Hypertension in Histiocytosis X. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 161, 216-223.	2.5	231
823	Imbalance between Platelet Vascular Endothelial Growth Factor and Platelet-derived Growth Factor in Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 162, 1493-1499.	2.5	90
824	Improvement of von Willebrand Factor Proteolysis After Prostacyclin Infusion in Severe Pulmonary Arterial Hypertension. <i>Circulation</i> , 2000, 102, 2460-2462.	1.6	65
825	Basophils, eosinophils, and mast cells in atopic and nonatopic asthma and in late-phase allergic reactions in the lung and skin. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 105, 99-107.	1.5	172
826	Treatment of pulmonary hypertension secondary to connective tissue diseases. <i>Thorax</i> , 1999, 54, 273-277.	2.7	88
827	The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences. <i>Trends in Immunology</i> , 1999, 20, 528-533.	7.5	308
828	Pulmonary hypertension related to drugs and toxins. <i>Current Opinion in Cardiology</i> , 1999, 14, 437.	0.8	14

#	ARTICLE	IF	CITATIONS
829	Expression of the IL-4 receptor $\alpha$ -subunit is increased in bronchial biopsy specimens from atopic and nonatopic asthmatic subjects. Journal of Allergy and Clinical Immunology, 1998, 102, 859-866.	1.5	75
830	Pulmonary Edema Complicating Continuous Intravenous Prostacyclin in Pulmonary Capillary Hemangiomas. American Journal of Respiratory and Critical Care Medicine, 1998, 157, 1681-1685.	2.5	161
831	Increased Expression of High Affinity IgE (Fc $\epsilon$ RI) Receptor- $\alpha$ Chain mRNA and Protein-bearing Eosinophils in Human Allergen-induced Atopic Asthma. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 233-240.	2.5	61
832	Nitric Oxide Deficiency in Fenfluramine- and Dexfenfluramine-induced Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 1061-1067.	2.5	102
833	Chemokine Macrophage Inflammatory Protein-1 $\alpha$ mRNA Expression in Lung Biopsy Specimens of Primary Pulmonary Hypertension. Chest, 1998, 114, 50S-51S.	0.4	68
834	Primary Pulmonary Hypertension Associated With the Use of Fenfluramine Derivatives. Chest, 1998, 114, 195S-199S.	0.4	97
835	Relationship between IL-4 and IL-5 mRNA Expression and Disease Severity in Atopic Asthma. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 704-708.	2.5	191
836	Allergen-induced recruitment of Fc $\epsilon$ RI $^+$ eosinophils in human atopic skin. European Journal of Immunology, 1997, 27, 1236-1241.	1.6	24
837	Contrasting effects of IL-4, IL-10 and corticosteroids on RANTES production by human monocytes. International Immunology, 1996, 8, 1587-1594.	1.8	60
838	INTRAPULMONARY PRODUCTION OF RANTES DURING REJECTION AND CMV PNEUMONITIS AFTER LUNG TRANSPLANTATION. Transplantation, 1996, 61, 1757-1762.	0.5	56
839	Secretion of the eosinophil-active cytokines interleukin-5, granulocyte/macrophage colony-stimulating factor and interleukin-3 by bronchoalveolar lavage CD4 $^+$ and CD8 $^+$ T cell lines in atopic asthmatics, and atopic and nonatopic controls. European Journal of Immunology, 1995, 25, 2727-2731.	1.6	108
840	PERFORIN AND GRANZYME B GENE-EXPRESSING CELLS IN BRONCHOALVEOLAR LAVAGE FLUIDS FROM LUNG ALLOGRAFT RECIPIENTS DISPLAYING CYTOMEGALOVIRUS PNEUMONITIS. Transplantation, 1994, 57, 1289-1292.	0.5	6
841	Serum Neopterin After Lung Transplantation. Chest, 1993, 103, 449-454.	0.4	56
842	IN SITU PRODUCTION OF INTERLEUKIN-6 WITHIN HUMAN LUNG ALLOGRAFTS DISPLAYING REJECTION OR CYTOMEGALOVIRUS PNEUMONIA. Transplantation, 1993, 56, 623-627.	0.5	38
843	Activation of Macrophages and Cytotoxic Cells during Cytomegalovirus Pneumonia Complicating Lung Transplantations. The American Review of Respiratory Disease, 1992, 145, 1178-1184.	2.9	42
844	Neonatal diagnosis of HIV infection. Lancet, The, 1991, 338, 631.	6.3	7
845	Right heart failure. , 0, , 32-47.		0
846	Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension. , 0, , 89-104.		1

#	ARTICLE	IF	CITATIONS
847	Erythrocytes are altered in pulmonary arterial hypertension. European Respiratory Journal, 0 , 2200506.	3.1	0
848	Severe pulmonary hypertension associated with chronic obstructive pulmonary disease Long-term results of a prospective French multicenter cohort. European Respiratory Journal, 0 , 2102897.	3.1	3